Embracing Wellness Beyond Healthcare

Every year on June 21, the world comes together to celebrate International Day of Yoga, recognizing the profound impact of yoga on physical, mental, and emotional well-being. More than just a form of exercise, yoga is a holistic practice that promotes harmony between the body and mind, encouraging a healthier and more balanced way of life.

At RELISYS, our commitment to improving lives extends beyond advancing medical technologies. We believe that true health encompasses prevention, wellness, and mindful living. International Day of Yoga serves as an important reminder that small, consistent steps towards healthier habits can lead to lasting benefits for individuals and communities alike.

Yoga as a Global Movement

Since the adoption of International Day of Yoga by the United Nations in 2014, India has championed yoga as a universal practice that transcends borders, cultures and religions, promoting peace, unity and wellness worldwide.

Theme for International Day of Yoga 2026:

Yoga for Healthy Ageing

The 2026 theme highlights the importance of maintaining physical vitality, mental resilience and emotional well-being throughout every stage of life. As populations across the globe continue to age, yoga offers a sustainable and accessible approach to healthy ageing by supporting mobility, balance, cardiovascular health, stress management and overall quality of life.

The Relevance of Yoga in Today’s World

In an increasingly fast-paced world, stress, sedentary lifestyles and chronic health conditions continue to impact millions of people globally. Yoga offers a simple yet effective way to counter these challenges by improving flexibility, strength, posture, breathing and mental resilience.

Regular yoga practice has been associated with:

• Improved cardiovascular health
• Better stress management and emotional well-being
• Enhanced flexibility and mobility
• Improved respiratory function
• Greater focus, mindfulness and productivity
• Better overall quality of life
• Improved balance and functional independence as we age

By integrating yoga into daily routines, individuals can take proactive steps toward maintaining both physical and mental wellness throughout their lives.

Healthy Hearts Through Healthy Habits

Cardiovascular diseases remain one of the leading health concerns worldwide. While medical innovations continue to transform treatment outcomes, prevention and lifestyle management remain equally important.

Yoga complements heart-healthy living by encouraging:

• Stress reduction
• Improved circulation
• Better blood pressure management
• Improving effective breathing
• Greater awareness of overall health and wellness

The combination of mindful movements, controlled breathing, and relaxation techniques supports a healthier lifestyle that can positively influence long-term cardiovascular well-being.

Wellness in the Workplace

Creating a culture of wellness is essential for fostering healthier, happier, and more productive workplaces. Encouraging employees to prioritize their physical and mental health contributes to improved engagement, reduced stress, and enhanced overall well-being of the employee as well as of the organization.

Simple practices such as stretching, mindful breathing, short meditation sessions, and regular physical activity can make a meaningful difference in daily life.

At RELISYS, we recognize the importance of promoting wellness and encouraging healthy habits that support both personal and professional growth.

A Collective Journey Towards Better Health

The International Day of Yoga is an opportunity to reflect on the importance of balance, mindfulness, and preventive healthcare. Whether through a dedicated yoga practice or small daily wellness habits, every step towards a healthier lifestyle contributes to a stronger and more resilient future.

As we celebrate International Day of Yoga 2026 and its theme, “Yoga for Healthy Ageing,” let us embrace the spirit of well-being, mindfulness and healthy living. By investing in our health today, we can build a future where people of all ages enjoy greater vitality, independence and quality of life.

Together, we can build a healthier future—one breath, one stretch and one mindful step at a time.

The post International Day of Yoga 2026: Nurturing Health, Balance and Well-Being appeared first on Relisys Medical Devices.

Frequently Asked Questions

What is an Applicable Policy in ISO 20417:2026?

An Applicable Policy refers to regulatory, legal, organizational, or standards-based requirements that influence the information supplied with a medical device.

Why did ISO 20417:2026 introduce the concept of Applicable Policy?

The concept was introduced to recognize that manufacturers must consider not only ISO 20417 requirements but also jurisdiction-specific regulations, guidance documents, and organizational policies.

How does Applicable Policy affect medical device labeling?

Manufacturers must ensure that labels satisfy both ISO 20417 requirements and applicable market-specific regulatory obligations.

Does Applicable Policy apply to Instructions for Use (IFUs)?

Yes. IFUs may need to incorporate information arising from risk management, regulatory requirements, usability engineering, cybersecurity assessments, and clinical evaluations.

How can manufacturers implement Applicable Policy requirements?

Organizations can establish an Applicable Policy Framework and maintain an Applicable Policy Matrix that links source requirements to labeling, IFUs, and other supplied information.

How does Applicable Policy relate to ISO 14971?

Many information requirements originate from risk control measures. Applicable Policy helps ensure that risk communication requirements remain aligned with ISO 14971 outputs and regulatory expectations.

• Nature of body contact
• Type of tissue contacted
• Duration of contact

Among these factors, exposure duration is a critical determinant of the biological endpoints that must be evaluated. Incorrect estimation of exposure duration can lead to:

• Under-testing (regulatory risk)
• Over-testing (unnecessary animal studies)
• Rejection during regulatory review
• Inadequate toxicological risk assessment

Exposure duration classification directly influences the biological endpoint selection table in ISO 10993-1:2025. Incorrect categorization can result in incomplete evaluation or unnecessary testing. Regulatory reviewers frequently assess exposure duration calculation as a critical step during technical documentation review.

Exposure Duration Categories

One of the most critical determinants in biological evaluation is how long the patient is exposed to the medical device materials. ISO 10993-1:2025 does not merely classify devices by their physical design or intended purpose — it categorizes them based on the total exposure period to a single patient.

This classification directly determines:

• The scope of biological endpoints
• The depth of toxicological assessment
• The need for systemic toxicity studies
• The potential requirement for chronic or carcinogenicity data

The standard defines three exposure duration categories:

Limited Exposure (≤ 24 Hours)

A device is considered limited exposure when the total duration of contact with the patient does not exceed 24 hours.

This exposure may occur:

• During a single continuous procedure (e.g., surgical instruments)
• As multiple short exposures within the same 24-hour period
• Through cumulative use that still does not exceed 24 hours total

The defining element is that total exposure time remains within a 24-hour maximum window for a single patient.

Why This Category Matters

Limited exposure devices are typically associated with acute biological risks. The body’s response is generally immediate and localized. Therefore, the evaluation focuses on:

• Cytotoxic potential
• Irritation or intracutaneous reactivity
• Sensitization potential

If the device contacts circulating blood, hemocompatibility endpoints may also apply.

However, ISO 10993-1:2025 makes it clear that even limited exposure devices require a risk-based assessment. Chemical characterization must still be performed to ensure no unexpected systemic risk exists.

Prolonged Exposure (> 24 Hours to 30 Days)

A device falls under prolonged exposure when the total exposure period exceeds 24 hours but does not exceed 30 days.

This duration significantly changes the biological risk profile. Once exposure extends beyond 24 hours, the probability of:

• Systemic absorption of leachables
• Subacute tissue responses
• Cumulative biological effects increases.

Exposure in this category may occur through:

• Continuous contact (e.g., indwelling catheter for 7 days)
• Daily repeated use
• Intermittent contact summed over time

Biological Implications

Prolonged exposure introduces the possibility of systemic toxicity. As a result, in addition to the endpoints required for limited exposure, evaluation may expand to include:

• Subacute toxicity
• Material-mediated pyrogenicity
• Expanded systemic toxicity considerations
• Chemical characterization and toxicological risk assessment

At this stage, ISO 10993-1:2025 strongly emphasizes integration with chemical characterization principles under ISO 10993-18 and application of risk management principles aligned with ISO 14971.

The transition from limited to prolonged exposure is not minor — it fundamentally changes the depth of evaluation required.

Long-Term Exposure (> 30 Days)

Devices are categorized as long-term exposure when total patient contact exceeds 30 days.

This includes:

• Permanent implants
• Long-term indwelling devices
• Devices used daily beyond 30 calendar days
• Chronic therapeutic systems

Why Long-Term Exposure Is Critical

Long-term exposure allows:

• Accumulation of chemical substances
• Chronic tissue responses
• Long biological half-life interactions
• Potential carcinogenic or reproductive effects

The body’s adaptive response over extended periods must be considered.

Therefore, biological endpoints may expand further to include:

• Subchronic or chronic toxicity
• Genotoxicity
• Carcinogenicity (if indicated by risk assessment)
• Reproductive and developmental toxicity
• Implantation studies (for implantable devices)

ISO 10993-1:2025 reinforces that such testing should be performed only when scientifically justified, with preference given to chemical characterization and toxicological risk assessment before initiating animal studies.

Understanding the three duration categories is only the first step. Accurate classification depends on correct calculation of total exposure period, especially for devices with repeated, daily, or intermittent use.

Calculation and Estimation of Exposure Duration

Correct categorization depends not only on understanding the three duration groups but also on accurately calculating the total exposure period in a single patient.

One of the most common regulatory deficiencies arises from miscalculating exposure duration.

ISO 10993-1:2025 clarifies that exposure duration must consider:

• Frequency of use
• Replacement cycles
• Total therapy duration
• Repeated contact patterns
• Bioaccumulation potential

It is not sufficient to rely on single procedure time.

Daily Contact

Daily contact occurs when a device contacts the patient every calendar day for any portion of that day.

Even if the contact is brief (for example, two hours per day), each day counts as one exposure day.

Calculation Principle

For daily contact devices:

The total exposure period equals the number of calendar days from the first to the last use in a single patient, including replacement of identical single-use devices.

This means:

• Five hours per day for 40 days = 40 exposure days
• Two hours per day for 10 days = 10 exposure days
• Lifetime daily therapy = long-term exposure

Why This Rule Exists

Without this clarification, manufacturers might incorrectly classify a device used five hours per day as limited exposure. ISO prevents such underestimation by requiring calculation based on calendar days, not hourly accumulation.

This approach reflects the biological reality that repeated daily exposure enables:

• Chemical accumulation
• Tissue adaptation
• Systemic absorption over time

Intermittent Contact

Intermittent contact occurs when there is a minimum of 24 hours between consecutive tissue contacts.

Examples include:

• Devices used once every three weeks
• Semi-annual therapeutic systems
• Repeated treatment sessions

Calculation Principle

For intermittent contact devices:

The total exposure period is determined by summing the number of contact days from the first to the last use in a single patient.

The length of contact on each day does not affect classification.

For example:

• 10 treatment sessions = 10 exposure days
• 6 treatments over 3 years = 6 exposure days

The elapsed calendar time (months or years) does not determine the category — the total number of contact days does.

Bioaccumulation Considerations

ISO 10993-1:2025 introduces important clarification regarding bioaccumulation.

Regardless of calculated exposure duration:

If a device contains materials known to:

• Persist in human tissue
• Accumulate over time
• Exhibit long biological half-life

Then the device may require classification as long-term exposure, unless scientifically justified otherwise.

This requirement ensures that toxicological risk assessment accounts for chemical persistence, even when apparent exposure duration seems limited or prolonged.

Bioaccumulation assessment should be documented within:

• The Biological Evaluation Plan (BEP)
• Toxicological Risk Assessment
• Risk Management File

Exposure Duration Determination Framework as per ISO 10993-1:2025

Exposure duration classification under ISO 10993-1:2025 is not a simple time-based labeling exercise — it is a scientifically grounded, risk-driven determination that directly influences the scope and depth of biological evaluation.

Correct categorization requires:

• Clear understanding of intended use
• Accurate calculation of total exposure period
• Consideration of daily versus intermittent contact
• Inclusion of replacement cycles
• Assessment of bioaccumulation potential

Misclassification can lead to regulatory delays, additional testing requirements, or worst-case, inadequate patient safety evaluation.

ISO 10993-1:2025 reinforces the importance of integrating exposure duration assessment with chemical characterization and toxicological risk assessment before initiating animal studies. This approach supports scientifically justified evaluation while minimizing unnecessary testing.

Ultimately, exposure duration is not merely a regulatory checkbox — it is a foundational element of biological risk assessment and patient safety.

When properly calculated and clearly documented, it strengthens both regulatory acceptance and clinical confidence in medical device safety.

Every February, Heart Month reminds us to pause and reflect on one of our most vital organs—the heart. Yet cardiovascular health is not a once-a-year conversation. Heart disease remains one of the leading causes of mortality worldwide, and its prevention, early detection, and treatment require year-round commitment, not momentary awareness.

As lifestyles evolve and risk factors rise, caring for the heart has never been more critical.

The Growing Burden of Heart Disease

Modern living has brought convenience—but also challenges. Sedentary habits, processed foods, chronic stress, diabetes, obesity, smoking, and hypertension continue to fuel the rise of cardiovascular diseases across age groups.

What makes heart disease especially dangerous is that it often progresses silently. Many individuals remain unaware until a major event such as a heart attack, stroke, or heart failure occurs. This reality reinforces a crucial truth:

Heart health is not seasonal—it’s lifelong.

Prevention Begins with Everyday Choices

The foundation of heart health lies in simple, consistent lifestyle practices:

• Choosing balanced, nutritious foods over highly processed options
• Staying physically active through walking, exercise, yoga, or sports
• Managing stress with mindfulness, adequate sleep, and mental wellness
• Avoiding tobacco and limiting alcohol consumption
• Monitoring key health markers such as blood pressure, blood sugar, cholesterol, and weight

These daily decisions significantly reduce cardiovascular risk and improve overall well-being.

Early Detection Saves Lives

Regular health check-ups play a vital role in preventing serious cardiac events. Early identification of risk factors allows timely intervention—often before irreversible damage occurs.

Routine screenings, cardiac evaluations, and proactive monitoring empower individuals to take control of their heart health long before symptoms appear.

When Innovation Meets Care

While prevention is powerful, access to advanced medical technology is equally essential when intervention becomes necessary.

At Relisys Medical Devices, engineering excellence drives innovation across cardiovascular care. As a comprehensive solution provider for Coronary Artery Disease, Structural Heart Disease and Peripheral Vascular Disease, Relisys develops advanced therapies including but not limited to –

• Drug-Eluting Stents
• Catheters and Coronary Accessories
• PTCA Balloon Catheters
• Transcatheter Heart Valve solutions

Each solution is designed with precision, safety, and patient outcomes at its core—supporting clinicians in delivering effective, life-saving care.

Heart Health Is a Shared Responsibility

Heart health extends beyond individuals. Healthcare professionals, medical technology innovators, organizations, and communities all play a vital role in building awareness, advancing care, and improving outcomes.

Heart Month serves as a reminder—but every month should be Heart Month and every day a Heart Day!

A Commitment Beyond February

As we observe Heart Month 2026, let it inspire more than conversations. Let it encourage lasting habits, regular screenings, and informed choices.

Because when it comes to the heart:
Every beat matters. Every day counts.

At Relisys, our commitment to advancing cardiovascular care continues—today, tomorrow, and all year long.

The post Heart Month 2026: Why Heart Health Deserves Year-Round Attention appeared first on Relisys Medical Devices.

4. The Most Common Reasons MDD Usability Files Fail MDR Reviews

During MDR transition assessments, the same usability gaps appear repeatedly.

Lack of Iterative Design Evidence

MDR expects usability engineering to be a lifecycle process, not a single event.

Common issues include:

• Formative evaluations were conducted
• Findings were addressed informally
• No documented rationale showing how user feedback influenced design, labeling, or IFU

Even a single improvement, such as clarifying instructions in the user manual, must be:

• Documented
• Justified
• Linked to risk reduction

“No Use Errors Observed” Without Objective Criteria

Statements like:

• “All tasks were completed successfully”
• “No critical use errors were identified”

often fail MDR scrutiny because they lack:

• Defined critical tasks
• Objective success criteria
• Pass/fail thresholds
• Performance measures (time, deviation, recovery)

Over-Reliance on Professional Users

A very common justification under MDD was:

“The device is used by trained healthcare professionals.”

MDR requires this claim to be proven, not assumed.

• Cognitive load
• Time pressure
• Environmental distractions
• Workflow interruptions
• Emergency conditions

Professional users still make errors, especially in high-throughput or stressful environments.

Weak Validation of IFU and Labeling

Under MDD, IFU was often treated as a paper mitigation.

Under MDR:

• IFU and labeling are part of the user interface
• Their effectiveness must be validated with users

Simply referencing the IFU in risk controls is no longer adequate.

Under MDR, usability is no longer assessed in isolation. It is examined in direct connection with:

• Risk management
• Clinical safety
• Real-world use conditions
• Lifecycle evidence

Most MDR usability findings do not arise because manufacturers failed to perform usability activities, but because:

• Assumptions were left implicit
• Evidence was insufficiently structured
• Traceability between risks, tasks, controls, and validation was weak

A successful MDR usability strategy focuses on:

• Clearly defining intended users, uses, and environments
• Identifying and justifying critical user tasks
• Demonstrating the effectiveness of usability-related risk controls
• Validating IFU and labeling as part of the user interface
• Aligning usability conclusions with clinical and PMS data

Importantly, MDR compliance does not automatically require repeating usability testing. When supported by a strong, risk-based justification and consistent lifecycle evidence, existing usability data can remain fully defensible.

When approached systematically, usability engineering becomes one of the strongest and most credible elements of MDR technical documentation—providing regulators with clear, objective assurance that the device can be used safely and effectively in real-world conditions.

As we approach the close of another remarkable year, Relisys Medical Devices extends heartfelt gratitude to all doctors, healthcare partners, and team members who have been part of our journey. Together, we strengthened cardiovascular innovation, improved patient outcomes, and made advanced therapies more accessible across India and beyond.

Celebrating Our 2025 Milestones

This year was truly transformative — a testament to our shared commitment to innovation, quality, and patient-centric care.

Landmark TAVI & TricValve Cases

Our continued success with the Vienna Aortic Valve SE and the TricValve Bicaval Valves System showcased procedural precision and reinforced our mission to redefine cardiac interventions. These achievements demonstrate how reliable, next-generation technologies can significantly improve patient lives.

Presence at Leading Conferences

Relisys proudly participated in several prestigious national and international cardiology conferences. Across each platform, we showcased our cutting-edge cardiovascular portfolio, engaged with global experts, and contributed to the evolving landscape of structural heart and interventional cardiology innovations.

Expanding Therapy Areas

The growing clinical adoption of our Pearl CB (Cutting Balloon) and Pearl DCB (Drug-Coated Balloon) highlighted the trust clinicians place in our devices. This year also marked the launch of MetaGraft AAA (Abdominal Aortic Stent Grafts) and MetaGraft TAA (Thoracic Aortic Stent Grafts)—both of which have been readily accepted by the medical fraternity for their role in managing life-threatening aortic conditions and improving patient survival.

Strengthening Our Purpose

At the core of every milestone is our belief that quality cardiovascular care should be accessible to all. Through continuous R&D, advanced manufacturing, and close collaboration with healthcare professionals, we are committed to delivering precision-engineered devices that empower clinicians and transform patient care.

A Global Step Forward: Relisys Goes to Egypt

A defining moment this year was the signing of an MoU to establish a state-of-the-art manufacturing facility in Egypt. The new facility will produce coronary vascular devices — including stents, balloons, and delivery accessories — to serve the Middle East and North Africa (MENA) region. This initiative reflects our larger mission to expand access, build local capacity and strengthen global healthcare ecosystems.

Sustainability & Social Responsibility

Our “Plastic-for-a-Tree” initiative on World Environment Day encouraged collective action toward sustainability, ending with a tree-planting drive at one of our factories.
On World Heart Day, we conducted a special awareness session on preventive heart health, reinforcing our dedication to education, wellness, and community care.

Elevate. Accelerate. 2025

Our FY 2025 theme — Elevate. Accelerate. — inspired teams to realign around bold ambitions and a clear roadmap for the future. With renewed purpose, we step into 2026 focused on innovation, collaboration, and better outcomes for patients worldwide.

A Heartfelt Thank You

Thank you, to the doctors who trust our devices, the partners who share our vision, and the teams who make it all possible. Here’s to new beginnings, stronger collaborations, and another year of transforming lives. Together, we’ll keep hearts beating stronger.

Wishing everyone a Healthy and Prosperous New Year 2026!

The post Year-End Reflections: Thank You for Being Part of the Journey appeared first on Relisys Medical Devices.

While the terminology may appear similar, medical device and IVD PMS/vigilance is fundamentally different from pharmaceutical pharmacovigilance (PV). The root of this difference lies in how these products work:

• Pharmaceuticals act through pharmacological, immunological, or metabolic mechanisms (PK/PD).
• Medical devices and IVDs are engineered products whose performance depends on design, materials, usability, software, and interaction with users—not on PK/PD.

This fundamental scientific distinction drives completely different regulatory philosophies for post-market safety monitoring, serious adverse event handling, and regulatory decision-making.

What Is PMS & Vigilance for Medical Devices and IVDs?

Post-Market Surveillance (PMS)

Post-Market Surveillance for medical devices and IVDs is a continuous, proactive, and systematic process designed to monitor a product’s real-world performance and safety throughout its entire lifecycle.

Key characteristics of device/IVD PMS include:

• Continuous collection and review of data after market placement

• Use of multiple real-world data sources, including:

  Customer complaints
• Service and maintenance data
• Registries and real-world evidence (RWE)
• Scientific literature
• Feedback from users and healthcare professionals
• Evaluation of trends, failure modes, and performance drift
• Implementation of corrective and preventive actions (CAPA) when required

• What data will be collected
• How it will be analysed

• How findings will feed back into:

  Risk management
• Clinical or performance evaluation
• Technical documentation
• Product improvement

World Heart Day, observed annually on September 29th, is a vital global initiative aimed at raising awareness about cardiovascular diseases (CVDs), which remain the leading cause of death worldwide. This day serves as a reminder of the importance of heart health and encourages individuals, communities, and governments to take proactive steps in combating heart-related issues. With a focus on awareness, self-care, lifestyle changes, technological advancements, and the crucial role of governments and organizations, World Heart Day is a call to action for all.

The Importance of World Heart Day

Cardiovascular diseases account for nearly 18 million deaths each year, highlighting the urgent need for awareness and prevention. World Heart Day provides a platform to educate people about the risks of heart disease and the steps they can take to reduce those risks. It also serves as a reminder that heart health is not just a personal responsibility but a collective one, involving families, communities, healthcare providers, and policymakers.

Raising Awareness

Awareness is the first step toward prevention. On World Heart Day, organizations worldwide engage in campaigns to inform the public about the signs, symptoms, and risk factors of heart disease. Educational programs, community events, and social media campaigns help spread the message, emphasizing that early detection and lifestyle modifications can significantly reduce the risk of heart disease.

The Importance of Self-Care

Self-care is a cornerstone of heart health. Regular exercise, a balanced diet, and stress management are essential components of a heart-healthy lifestyle. World Heart Day encourages individuals to take charge of their health by making informed decisions about their diet, engaging in physical activity, and avoiding harmful habits like smoking and excessive alcohol consumption. Simple changes, such as incorporating more fruits and vegetables into meals or taking a daily walk, can have a profound impact on heart health.

Lifestyle Changes for Heart Health

Lifestyle changes are critical in preventing and managing heart disease. Reducing salt intake, maintaining a healthy weight, managing blood pressure, and controlling cholesterol levels are all essential steps in protecting the heart. World Heart Day serves as a reminder that even small, incremental changes can lead to significant improvements in heart health over time. The day also encourages people to schedule regular check-ups and screenings to monitor their heart health.

The Role of Technology

Advancements in technology have revolutionized heart health care. From wearable devices that monitor heart rate and activity levels to telemedicine platforms that provide remote consultations, technology is making it easier for people to manage their heart health. World Heart Day highlights the importance of embracing these innovations to enhance the prevention, diagnosis, and treatment of cardiovascular diseases. The integration of artificial intelligence in predictive analytics and personalized medicine is also opening new avenues for targeted interventions and improved outcomes.

Role of Governments and Organizations

Governments and organizations play a crucial role in improving heart health in a number of ways. Governments can create policies to promote cardiovascular health, such as:

• Regulation: Regulating potentially harmful products 
• Integrated care: Creating multidisciplinary care pathways, such as cardiac rehabilitation programs 
• Tobacco taxes: Raising taxes on tobacco 
• Tobacco advertising bans: Enforcing bans on tobacco advertising, promotion, and sponsorship

On World Heart Day, Governments can launch health communication campaigns to raise awareness and encourage healthy behaviors. Governments and health organizations are urged to prioritize heart health in their agendas, implementing policies that promote healthy living and ensuring access to quality healthcare for all.

Role of Medical Devices

On World Health Day, the pivotal role of medical devices in advancing global healthcare is highlighted. These technologies enable early diagnosis, effective management of chronic conditions and precise surgical interventions, significantly improving patient outcomes. From wearable health trackers to advanced imaging systems, medical devices enhance access to quality care, particularly in underserved areas. By supporting public health initiatives and bridging healthcare gaps, they are essential tools in the fight for better health worldwide.

Conclusion

World Heart Day is more than just a date on the calendar; it is a powerful reminder of the importance of heart health and the collective actions needed to combat cardiovascular diseases. By raising awareness, encouraging self-care, promoting lifestyle changes, embracing technology, and advocating for supportive policies, we can make a significant impact on global heart health. This World Heart Day, let’s use our hearts for action—because every beat count.

The post World Heart Day: A Global Call to Action for Heart Health appeared first on Relisys Medical Devices.

As we commemorate World Organ Donation Day, it’s essential to reflect on the profound impact that organ donation has on countless lives. The heart transplant, a complex surgical procedure that replaces a failing heart with a healthy donor heart, is one of the most amazing and remarkable life-saving procedures resulting from organ donation.

The Impact of Organ Donation

Organ donation is a selfless act that can save up to eight lives, and a heart donation embodies the gift of life. When a donor heart becomes available, it undergoes a rigorous matching process to ensure compatibility with the recipient, reducing the risk of rejection and improving the chances of a successful transplant.

The Need for Heart Transplants

Heart disease remains one of the leading causes of death globally. For many patients with severe heart conditions, medication, and less invasive procedures may not suffice. A heart transplant can be the only option to extend and improve the quality of their lives. However, the availability of donor hearts is critically low compared to the need, making organ donation vital.

The Heart Transplant Procedure

Evaluation and Listing: Patients undergo an extensive evaluation to determine their eligibility. Once deemed suitable, they are placed on the transplant waiting list.

• Donor Matching: When a donor heart becomes available, it is matched based on blood type, body size, and the urgency of the recipient’s condition.
• Surgery: The transplant surgery involves removing the diseased heart and implanting the healthy donor heart. This complex procedure requires a highly skilled surgical team and can last several hours.
• Post-Surgery Care: Postoperative care is crucial for the patient’s recovery. This includes immunosuppressive medications to prevent rejection, regular monitoring, and lifestyle adjustments.

The Role of Donors and Their Families

None of this would be possible without the generosity of organ donors and the consent of their families. Their decision to donate during a time of grief provides hope and new life to others. Each donor’s heart represents a legacy of kindness and compassion.

Raising Awareness

World Organ Donation Day is an opportunity to raise awareness about the importance of organ donation. It encourages people to register as organ donors and discuss their wishes with family members. Increased awareness and registration can significantly reduce the waiting time for transplants and save more lives.

Conclusion

A heart transplant is more than a medical procedure; it is a beacon of hope for those battling severe heart conditions. On this World Organ Donation Day, let’s honor the donors and their families who make these life-saving transplants possible. Consider becoming an organ donor and help transform lives. Your decision can create a lasting impact, giving someone the precious gift of life and a second chance to experience life’s wonders.

The post Heart Transplant: A Lifesaving Miracle on World Organ Donation Day appeared first on Relisys Medical Devices.

As we wrap up another remarkable year at Relisys Medical Devices, we reflect on our journey of progress and innovation in cardiovascular therapies. The year 2024 has been an exceptional journey of progress, collaboration and innovation, marking significant milestones in the field of structural heart, coronary & peripheral vascular therapies. From pioneering TricValve procedures to introducing Vienna Aortic Valve SE, our endeavors have redefined possibilities in interventional cardiology as we continued our mission to make a positive impact on patient lives.

Expanding Access Through the TAVI Roadshow

One of the highlights of 2024 was our TAVI Roadshow, which spanned multiple cities across India. This initiative brought together cardiologists, healthcare professionals, and patients, creating a platform to demonstrate the effectiveness of the Vienna Aortic Valve SE therapy, in addressing a diverse range of anatomical challenges offering a minimally invasive solution for patients with severe aortic stenosis.

Pioneering TricValve Therapies Globally

Our TricValve therapy continued to make significant inroads in 2024, addressing the unmet needs of patients with tricuspid regurgitation. Notable milestones included successful procedures in India & elsewhere, where patients experienced life-changing improvements in their quality of life. These achievements were further amplified by impactful presentations at global platforms such as International Conferences, Exhibitions & Symposiums in Hospitals, where renowned Cardiologists presented the effectiveness of our devices.

Global Collaboration and Knowledge Sharing

The year 2024 was also defined by robust global collaborations. At many conferences, we engaged with industry leaders, physicians, and business partners, sharing insights on our cutting-edge technologies. Our active participation in these events reinforced our position as a trusted partner in the medical device industry, driving innovation and excellence in manufacturing.

State-of-the-Art Manufacturing and New Product Launches

Our state-of-the-art integrated manufacturing facility has been a cornerstone of our success, enabling us to produce high-quality medical devices that meet global standards.

This year, we marked significant milestones with new product launches across coronary, peripheral, and structural heart divisions, reaffirming our commitment to innovation in cardiovascular care and further enhance treatment options for patients with complex cardiovascular conditions. From advanced stent technologies to life-transforming therapies, our portfolio continues to address critical patient needs. These launches signify our dedication to providing cutting-edge solutions that improve outcomes and redefine possibilities in modern healthcare.

Improving Patient Lives and Outcomes

At Relisys Medical Devices, improving patient lives and outcomes remains at the core of everything we do. Through innovative therapies like the TricValve^® and Vienna Aortic Valve SE^®, we’ve transformed complex cardiac conditions into treatable possibilities, offering new hope to patients worldwide. By combining cutting-edge technology, collaboration with healthcare professionals, and a commitment to excellence, we continue to enhance the quality of life for those who need it the most.

Building Scientific Evidence for our Devices through Clinical Studies

We made significant strides in building scientific evidence for our devices through rigorous clinical studies and registries.

• We have successfully completed the enrolment & follow-up of >1000 patients for the post-marketing surveillance study that we have undertaken with our premium drug-eluting stent, PRISTINE+. This study has provided real-world insights into our device performance, safety & efficacy which is nothing less than the best. The Pristine+ Registry has been a forerunner for building scientific evidence for our devices.
• Post-market clinical Follow-up (PMCF) studies on our advanced balloons and catheters have reaffirmed their exceptional safety and reliability.
• The TRIO2 Study has been commenced marking an era in the scientific compilation of the safety and efficacy of TRICVALVE®, Transcatheter Bicaval Valves System in the Indian population with Tricuspid Regurgitation.
• Ongoing VIVA GLOBAL & VIVA INDIA Studies are evaluating the safety and efficacy of the Vienna Aortic Valve SE, a Transcatheter self-expandable Aortic Valve System in the Indian population with severe Aortic Stenosis.

These initiatives reflect our unwavering commitment to advancing evidence-based cardiovascular care and our commitment to HUMAN LIFE.

Looking Ahead

As we end 2024 successfully, we extend our gratitude to all our partners, collaborators, and healthcare professionals for their unwavering support. With a focus on expanding access to life-saving therapies, strengthening global collaborations, and investing in cutting-edge research and development, we are poised to make 2025 even more remarkable.

Wishing everyone a Healthy and Prosperous New Year 2025!

The post Wrapping up the journey of a remarkable year 2024! appeared first on Relisys Medical Devices.

Every year, on April 7^th, the world unites to celebrate World Health Day, an initiative led by the World Health Organization (WHO) to raise awareness about pressing global health issues. In 2025, the focus is on one of the most crucial aspects of healthcare—maternal and new-born health. Under the campaign theme “Healthy Beginnings, Hopeful Futures”, this year-long initiative aims to urge governments, healthcare providers, and communities to eliminate preventable maternal and new-born deaths while prioritizing women’s long-term health and well-being.

The Urgent Need for Action

Despite significant medical advancements, maternal and new-born mortality remains a critical challenge worldwide. According to WHO, hundreds of thousands of women and new-borns lose their lives each year due to preventable complications during pregnancy, childbirth, and the postnatal period. Many of these deaths occur in low-resource settings where access to quality healthcare services is limited.

Key contributing factors to maternal and new-born deaths include:

• Inadequate prenatal care
• Lack of skilled birth attendants
• Postpartum complications
• Limited access to essential medicines and interventions
• Poor nutritional and mental health support for mothers
• Prioritizing Women’s Health Beyond Childbirth

The campaign goes beyond childbirth safety; it highlights the importance of long-term health and well-being for women. Postpartum care, mental health support, and access to healthcare services are essential in ensuring that mothers continue to lead healthy lives after delivery. Conditions such as postpartum depression, heart disease, and diabetes require continued attention and care, reinforcing the need for stronger healthcare systems that cater to women’s health at every stage of life.

Call to Action: How Can We Contribute?

To achieve the goals of Healthy Beginnings, Hopeful Futures, collaboration is key. Governments, healthcare organizations, NGOs and individuals all have a role to play in ensuring a safer future for mothers and new-borns.

1. Strengthening Healthcare Systems: Investing in maternal healthcare infrastructure, skilled healthcare professionals, and essential medical supplies is critical in reducing maternal and new-born deaths.

2. Enhancing Community Awareness: Education and awareness programs can empower women with knowledge about prenatal and postnatal care, helping them make informed health decisions.

3. Supporting Innovations in Maternal Healthcare: The use of digital health solutions, remote monitoring, and AI-driven healthcare technologies can improve access to care and timely interventions.

4. Advocating for Policy Changes: Governments must prioritize maternal and new-born health policies, ensuring access to universal maternal healthcare services for all women, regardless of their socio-economic background.

A Future of Healthy Beginnings

World Health Day 2025 serves as a reminder of our collective responsibility to protect and support mothers and new-borns. By prioritizing accessible, equitable, and quality maternal healthcare, we can lay the foundation for a future where every mother and baby has the opportunity to thrive.

Let’s work together to create healthy beginnings and hopeful futures for generations to come!

The post World Health Day 2025: Healthy Beginnings, Hopeful Futures! appeared first on Relisys Medical Devices.

Heart disease is often perceived as a men’s health issue, but it is also the leading cause of death for women globally. Despite this, many women remain unaware of their risks and the steps they can take to protect their heart health. Raising awareness and empowering women with the right knowledge can lead to better prevention, early detection and timely treatment.

Understanding the Unique Risks for Women

Women’s heart disease can present differently than men. Some unique risk factors include:

• Hormonal changes: Estrogen provides some heart protection, but its decline after menopause increases cardiovascular risk.
• Pregnancy-related complications: Conditions like gestational diabetes, pre-eclampsia and high blood pressure during pregnancy can increase the risk of heart disease later in life.
• Autoimmune diseases: Women are more likely than men to have autoimmune conditions like lupus and rheumatoid arthritis, which can contribute to heart disease.
• Mental health: Depression, anxiety and chronic stress, which are more common in women, have been linked to higher incidence of heart disease risks.

Recognizing the Symptoms

Unlike men, who often experience classic chest pain during a heart attack, women may have subtler symptoms, including:

• Shortness of breath
• Unexplained fatigue
• Dizziness or nausea
• Pain in the neck, jaw, or upper back
• Cold sweats
• Indigestion-like discomfort

Since these symptoms can be mistaken for less severe conditions, many women delay seeking medical help. Raising awareness about these signs can lead to quicker intervention and better outcomes.

Preventative Measures: How Women Can Take Charge

Taking proactive steps can help women protect their heart health:

Maintain a Heart-Healthy Diet: Eat more fruits, vegetables, whole grains, and lean proteins. Limit processed foods, added sugars, and trans fats. Include healthy fats from sources like olive oil, nuts, and avocados.

Exercise Regularly: Aim for at least 150 minutes of moderate exercise per week. Activities like brisk walking, yoga, strength training and swimming can improve heart health.

Manage Stress & Mental Health: Practice stress-reducing techniques like meditation, deep breathing, or mindfulness. Seek support for anxiety or depression, as mental health directly impacts heart health.

Know Your Numbers: Monitor blood pressure, cholesterol, blood sugar and body weight regularly.

Quit Smoking & Limit Alcohol: Smoking significantly increases heart disease risk. Alcohol should be consumed in moderation, as excessive intake can contribute to high blood pressure.

Prioritize Regular Check-Ups: Women should schedule annual heart health screenings, especially if they have risk factors. Discuss any family history of heart disease with a doctor to assess genetic risks.

Spreading Awareness & Supporting Women’s Heart Health: Encourage conversations about heart health among family and friends. Participate in community events focused on women’s cardiovascular health.

Conclusion

Women can take charge of their heart health by staying informed, making lifestyle changes and advocating for early detection and treatment. By prioritizing self-care and spreading awareness, we can empower more women to live heart-healthy lives and reduce the burden of cardiovascular disease.

RELISYS is committed to empowering women’s heart health by raising awareness and providing cutting-edge cardiovascular solutions.

Together, we strive to make a difference in women’s lives by ensuring better heart care and improved outcomes. Happy International Women’s Day!

The post Raising Awareness: How Women Can Take Charge of Their Heart Health appeared first on Relisys Medical Devices.

Every year on June 14, the world comes together to recognize and appreciate the silent heroes among us—voluntary blood donors. World Blood Donor Day is more than just a celebration; it’s a reminder of how one selfless act can save multiple lives.

At Relisys Medical Devices, we believe in not only advancing life-saving medical technology but also fostering a culture of care and responsibility. Over the years, we’ve organized numerous blood donation drives, contributing to the urgent need for safe blood and helping save many lives.

Why Blood Donation Matters

• Every 2 seconds, someone needs blood—whether it’s due to surgery, trauma, cancer treatment, or chronic illness.
• A single donation can help save up to three lives.
• Blood cannot be manufactured; it can only come from generous donors.

Blood Donation and Heart Health

Did you know that donating blood may also benefit the heart? Regular blood donation can:

• Improve cardiovascular health by reducing excess iron in the blood
• Help maintain healthy blood flow(improved circulation) and reduce oxidative stress
• Encourage routine health check-ups, which contribute to early detection of health risks

For patients suffering from cardiac conditions, especially those undergoing complex interventions, safe and timely blood availability can be life-saving.

Our Commitment at RELISYS

As a trusted partner in cardiac care and innovation, we understand the critical role that blood plays in interventional cardiology procedures. Whether it’s during TAVI, TricValve, or complex vascular interventions, blood support is essential.

Our blood donation camps—organized across units and locations—have not only supported hospitals and patients but also promoted awareness among our employees and community.

Be a Lifesaver

This World Blood Donor Day, we urge you to:

• Donate blood regularly
• Encourage friends and family to become donors
• Spread awareness on social media and in your community

Together, let’s continue to build a healthier, stronger society—one drop at a time.

The post World Blood Donor Day: Donate Blood, Save Lives, Strengthen Hearts! appeared first on Relisys Medical Devices.

Liver Disease & Heart Health: A Vital Connection You Shouldn’t Ignore

Every year on July 28, World Hepatitis Day reminds us of the global burden of liver disease and the importance of liver health. But what many don’t realize is that the liver and the heart are deeply connected—and liver disease can silently impact cardiovascular health.

At Relisys, we believe that understanding this liver-heart link can empower patients, families, and physicians to take preventive steps and improve outcomes.

Why the Connection Matters

Liver and heart are partners in keeping the body healthy. While the liver filters toxins and manages metabolism, the heart ensures nutrients and oxygen are delivered across the body—including to the liver itself. When liver function is compromised (especially due to hepatitis-related diseases), it creates a ripple effect on the cardiovascular system.

How Liver Disease Affects the Heart

Patients with chronic liver diseases, including Hepatitis B and C, face an increased risk of:

• Heart failure (especially in advanced liver damage or cirrhosis)
• Arrhythmias and low blood pressure
• Pulmonary hypertension due to back-pressure from liver dysfunction
• Congestive hepatopathy from severe right heart failure or tricuspid valve issues

In fact, severe tricuspid regurgitation can lead to liver congestion, creating a complex heart-liver loop that demands specialized structural interventions.

Fatty Liver and the Hidden Cardiovascular Risk

Hepatic steatosis, or fatty liver, is a common metabolic condition often seen as benign — but emerging research tells a different story. In the context of cardiovascular–kidney–metabolic (CKM) syndrome, its impact may be significantly underestimated. A recent study revealed that a higher Fatty Liver Index (FLI) — a simple and cost-effective measure of hepatic steatosis — was consistently associated with increased risks of cardiovascular events (heart failure, stroke & myocardial infarction) and overall mortality, regardless of the stage of CKM syndrome.

The Cardio-Hepatic Loop: Clinical Insight

We now see a growing need for interdisciplinary care, where cardiologists and hepatologists work together to manage patients with dual organ involvement.

Structural heart solutions, like the TricValve® Bicaval Valve System, are emerging as potential therapy options for patients suffering from congestive hepatopathy due to advanced TR (tricuspid regurgitation).

By managing the root cause in the heart, we’re seeing improved liver function and better quality of life in selected patients.

Protecting Both: What Can We Do

On this World Hepatitis Day, here’s how we can protect the liver and heart together:

• Get screened for Hepatitis B & C: Early diagnosis is key to preventing chronic liver complications.
• Maintain a liver-healthy lifestyle: Eat a balanced diet, avoid alcohol, and stay physically active.

Managing cardiovascular risk:

• Control blood pressure, blood sugar, and cholesterol levels.
• Talk to the doctor about both organs
• In case of chronic heart or liver issues, ensure both are monitored together.

World Hepatitis Day is not just about fighting liver disease — it’s about recognizing how deeply connected our organs are. By protecting our liver, we’re also taking a step toward a healthier heart.

Let’s raise awareness, encourage screenings, and promote integrated care — for a healthier tomorrow.

The post Liver Disease & Heart Health: A Vital Connection You Shouldn’t Ignore appeared first on Relisys Medical Devices.

Every year on September 16, the world recognizes the International Day for Interventional Cardiology—a moment to celebrate the advancements that have transformed the treatment of heart disease and improved millions of lives globally.

Interventional cardiology has revolutionized care by offering minimally invasive solutions for complex cardiovascular conditions. From coronary angioplasty to advanced transcatheter therapies, these innovations provide patients with safer options, faster recovery and better quality of life.

RELISYS: At the Core of Interventional Cardiology

At Relisys Medical Devices, we are proud to stand at the forefront of this life-saving speciality. Our comprehensive portfolio empowers Interventional Cardiologists with cutting-edge technologies designed to deliver precision, reliability, and desired treatment outcomes.

• State-of-the-art Stents: Built with advanced engineering for safety, efficacy, and performance.
• Catheter Range: From diagnostic catheters to therapeutic and delivery catheters, including cutting balloons and drug-coated balloons, our solutions enable accurate navigation and effective treatment across diverse anatomies for diverse pathologies.
• Endovascular Stent Grafts: Offering durable support and treatment for complex vascular conditions.
• Structural Heart Therapies: From the ground-breaking TricValve (CAVI system) for severe tricuspid regurgitation to the Vienna Aortic Valve SE (TAVR system), RELISYS innovations provide minimally invasive options for patients once considered inoperable.
• Comprehensive Accessories: Introducer sheaths, manifolds, dilatation balloons etc. are few therapy delivery products that are designed to ensure seamless procedural efficiency.

Innovation Driven by Patient Care

Through advanced design, deep clinical insight, and world-class manufacturing, we create devices that ensure:

• Minimally invasive procedures that enable faster recovery times.
• Clinical adaptability to tackle even the most complex cardiovascular conditions.
• Reliability and consistency that empower physicians to deliver with confidence.

Shaping the Future of Cardiovascular Care

At RELISYS, Innovation is not just about technology—it’s about transforming patient outcomes and empowering physicians with devices that make a real difference. We are committed to advancing next-generation solutions that are redefining the landscape of interventional cardiology and offering safer, more effective alternatives to traditional surgery.

With each advancement, RELISYS is not only pushing the boundaries of technology but also ensuring accessibility and affordability—bringing world-class cardiovascular care closer to patients in India and across International markets.

Our Commitment

On this International Day for Interventional Cardiology, RELISYS reaffirms its dedication to supporting Interventional cardiology fraternity worldwide, empowering patient care, and advancing technology to meet the challenges of today for a healthier tomorrow!

The post International Day for Interventional Cardiology: Advancing Innovation, Patient Care, and Life-Saving Therapies appeared first on Relisys Medical Devices.

Introduction

Every year on November 14, the world observes World Diabetes Day — a global initiative by the International Diabetes Federation and the World Health Organization (WHO) to raise awareness about diabetes and its complications.

This year’s theme, “Access to Diabetes Care,” highlights the urgent need for early diagnosis, education, and timely treatment to prevent severe complications, especially those affecting the heart.

What is Diabetes?

Diabetes Mellitus is a chronic condition where the body cannot effectively regulate blood sugar levels. Over time, high blood sugar damages vital organs such as the heart, kidneys, eyes, and the nerves.

The two common types are:

• Type 1 Diabetes – The body fails to produce insulin. This is also called IDDM, Insulin-Dependent Diabetes Mellitus
• Type 2 Diabetes – The body becomes resistant to insulin or produces it inadequately. This is also called NIDDM, Non-Insulin Dependent Diabetes Mellitus

The Heart–Diabetes Connection

Diabetes and heart disease are closely linked. People with diabetes are 2–4 times more likely to develop cardiovascular conditions.
Chronic high blood sugar leads to inflammation and arterial damage, making arteries less flexible and prone to blockages. It also raises the risk of high blood pressure, obesity, and cholesterol imbalance — all key drivers of heart attacks and strokes.

Prevention and Management

Small lifestyle changes can prevent diabetes and reduce heart risks:

1. Choose a balanced, low-calorie diet
2. Stay physically active daily, exercise at least 30 minutes a day
3. Maintain a healthy weight, keep BMI under control
4. Avoid smoking and alcohol
5. Schedule regular health check-ups
6. Manage stress and sleep effectively

Relisys Medical Devices: Advancing Heart Health

At Relisys Medical Devices, we’re committed to improving outcomes for diabetic patients at risk of heart disease.
Our innovations — including Drug Eluting Stents, Catheters, Balloons, and Transcatheter Heart Valves (TAVI & CAVI) — are designed to improve cardiac function, and enhance quality of life.

Through continuous innovation and collaboration with clinicians, we aim to ensure better heart care for all.

Conclusion

On this World Diabetes Day, let’s remember: small lifestyle choices create a big impact.
Stay active, eat healthy, and monitor your health — because a stronger heart starts with you.

Together, let’s protect hearts and prevent diabetes-related complications.

The post World Diabetes Day 2025: Understanding the Link Between Diabetes and Heart Health appeared first on Relisys Medical Devices.

Every year, World Heart Day is observed on 29^th September to raise awareness about cardiovascular health and inspire people across the globe to take proactive steps in protecting the hearts. The 2025 theme, “Don’t Miss a Beat!”, couldn’t be more relevant in today’s scenario, as the world is witnessing a surge in sudden cardiac arrests and heart attacks among young adults.

Why World Heart Day Matters

Cardiovascular diseases (CVDs) remain the leading cause of mortality worldwide, responsible for millions of deaths each year. Globally, the burden of heart disease is steadily increasing due to lifestyle changes, stress, poor diet and lack of regular exercise. By spreading awareness and empowering individuals with knowledge, we can collectively reduce the risks and improve heart health outcomes.

Don’t Miss a Beat – What It Means

The theme encourages everyone to:

• Recognize Warning Signs – chest pain, breathlessness, palpitations, unexplained fatigue.
• Adopt Prevention – healthy eating, at least 30 minutes of exercise daily, managing stress.
• Seek Timely Care – routine check-ups, monitoring blood pressure, cholesterol, and sugar.

Global Alarming Trends in Cardiac Disease

1. Leading Cause of Death – Cardiovascular diseases (CVDs) remain the No.1 cause of death worldwide, accounting for ~17.9 million deaths annually (WHO).
2. Younger Population at Risk – More cases of sudden cardiac arrest and heart attacks are reported in people under 40 years, driven by stress, lifestyle, and obesity.
3. Urban Lifestyle Factors – Poor diet, physical inactivity, smoking, alcohol, and stress are fuelling heart disease in both developed and developing countries.
4. Rising Diabetes & Hypertension – Over 1.3 billion adults worldwide have hypertension, many undiagnosed and untreated — a major risk factor for heart attacks and strokes.
5. Sedentary Work Culture – Post-pandemic work-from-home lifestyles and reduced physical activity are linked to higher cardiac risk.
6. Gender Shift – Increasing cases in women, especially due to delayed diagnosis and atypical symptoms being overlooked.

Alarming Trends in India

1. High Burden of CVDs – Cardiovascular diseases are the number one cause of mortality in India, accounting for 28% of all deaths.
2. Sudden Deaths in Young Adults – Multiple reports of sudden cardiac deaths during workouts, sports, or daily activities in 20’s and 30’s age groups.
3. Growing Risk Factors – India has the second-highest number of diabetics worldwide, coupled with rising obesity and high cholesterol.
4. Work Stress & Pollution – High stress jobs, lack of exercise, and air pollution are now recognized as major contributors to cardiac risk.

RELISYS: Advancing Solutions That Save Lives

At Relisys Medical Devices, we believe no life should be lost to preventable or treatable heart disease. Our innovations — from coronary stents, catheters, balloons to advanced therapies like TAVI, CAVI have been designed to ensure patients don’t miss a beat when it comes to living healthier & longer.

‘Take a Step Today!’

This World Heart Day, let’s pledge to ‘Take a Step Today’ to –

• Eat mindfully and avoid junk food
• Eat more fruits and vegetables
• Walk at least 30 minutes daily
• Quit smoking and reduce alcohol
• Prioritize sleep and mental well-being
• Go for regular check-ups
• Encourage friends, family, and colleagues to get regular heart check-ups

Our heart matters. Don’t Miss a Beat – act now, live longer, live healthier.

Together, let’s build a healthier future, one heartbeat at a time.

The post World Heart Day 2025 – Don’t Miss a Beat! appeared first on Relisys Medical Devices.

Types of Biosafety Cabinets

Class I BSCs

Class I BSCs provide personnel and environmental protection but do not offer product protection. They have an inward airflow to protect the user and HEPA-filtered exhaust air to protect the environment. These cabinets are suitable for work with low to moderate-risk agents where product sterility is not a concern.

Class II BSCs

Class II BSCs are the most commonly used cabinets in laboratories. They offer both product and environmental protection and are divided into four types:

• Type A1: Recirculates 70% of the air within the cabinet through HEPA filters, suitable for work with non-volatile toxic chemicals and radionuclides.
• Type A2: Similar to Type A1 but with higher face velocity, providing increased protection.
• Type B1: Exhausts 70% of the air through HEPA filters, used for work with volatile toxic chemicals in small amounts.
• Type B2: 100% of the air is exhausted through HEPA filters, ideal for work with volatile toxic chemicals and radionuclides.

Class II BSCs are essential in clinical, pharmaceutical, and research laboratories due to their comprehensive protection capabilities.

Class III BSCs

Class III BSCs, also known as glove boxes, provide the highest level of protection. They are completely enclosed, and operations within the cabinet are conducted through attached gloves. These cabinets are used for high-risk pathogens and bioweapons research, ensuring maximum containment.

Applicable International Standards

• ISO 14644: Cleanrooms and associated environments.
• ISO 13485: Quality management systems for the design and manufacture of medical devices.
• NSF/ANSI 49: Specific to biosafety cabinetry performance in the U.S.
• IEC 61010-1: Safety requirements for electrical equipment for measurement, control, and laboratory use.

Design Considerations

Classification of Biological Safety Cabinets (per NSF / ANSI Standard 49)

* Open front cabinets (e.g. Class II BSC) can still be used in BSL 4 facilities but will require positive-pressured personnel suit for laboratory users. 

** EN 12469 only recognizes Class I, Class II and Class III BSCs; Class II BSC Inflow velocity requirement as per EN 12469: ≥0.40 m/s

Applications with work zone ISO Class requirement

Selection of a Safety Cabinet through Risk Assessment

A BSC should be selected primarily according to the type of protection required: product protection; personnel protection against Risk Group 1–4 microorganisms; personnel protection against exposure to radionuclides and volatile toxic chemicals; or a combination of these. Below table shows which BSCs are recommended depending on the necessary type of protection;

Performance Testing BSCs in the Field

All Biological Safety Cabinets are to be verified to the current NSF/ANSI Standard 49, Annex F or EN12469 upon installation and annually thereafter. The purpose and acceptance level of the operational tests ensure the equalization of inflow and exhaust air, the circulation of air onto the work surface, and the integrity of the cabinet and the filters. Other tests monitor the BSCs electrical and physical features.

Downflow Velocity Test: This test determines the velocity of air traveling through the cabinet workspace.6 The EN12469 indicates a permissible downflow velocity range of 0.25-0.50m/s, whereas the NSF49 does not specify any downflow velocity requirement. A Thermo-anemometer shall be used to carry out the test in accordance with NSF49 while the EN12468 does not specify the test instrument accuracy and type.

Inflow Velocity Test: This test determines the average speed of air entering the cabinet. To carry out the test, direct inflow measurement (DIM) instrument shall be used to measure the inlet volumetric flow rate on the front aperture at nominal operating speed (primary method) and Thermal anemometers or pitot tubes or both shall be used to verify the calculated inflow velocity (secondary method) in accordance to NSF49. The European method for measuring the rate of inflow is performed above the exhaust filter. Both EN12469 and NSF49 specify minimum requirements for inflow velocity. For Class II Type A2 cabinets, the NSF49 specifies a minimum inflow rate of 0.5 m/s, whereas the European Standard requires 0.4 m/s for Class II cabinets.

Airflow Smoke Pattern Test: This test determines 

• whether the movement of the air along the entire perimeter of the work access opening is inward 
• whether the movement of the air within the working area is downward with no dead spots or refluxing 
• whether ambient air flows onto or over the work surface 
• whether airflow within the cabinet does not escape outside at the sides and top of the sash. A suitable smoke generator shall be used to visualize the cabinet’s airflow pattern.

HEPA/ULPA Filter Leak Test: This test determines the integrity of supply and exhaust HEPA filters, filter housing and filter mounting frames. To carry out the test, an aerosol generator shall be used to evenly distribute the aerosol throughout the supply (positive) cabinet plenum and an aerosol photometer shall be used to monitor aerosol penetration downstream of the filter, and to scan for the presence of leaks in accordance to NSF49. The European Standard allows an alternative test using the natural challenge test.

Light Intensity Test: This test determines the intensity of light on the work surface of the cabinet. A light intensity meter is used to obtain light levels at the cabinet work surface. NSF49 allows a slightly lower lighting level of 650 lux whereas the EN standard requires 750 lux.

Noise Level Test: This test determines the noise levels produced by the cabinets. With the cabinet running under regular parameters, a calibrated noise level meter shall be used to obtain a noise level of the cabinet during normal operation. The EN12469 test method specifies a distance further away from the cabinet as compared to the NSF49. The EN12469 allows up to 65dBa whereas the NSF49 allows up to of 67dBa.

Vibration Test: This test determines the amount of vibration in an operating cabinet. Vibration testing meter shall be used to verify the vibration level at the work tray

UV Radiation Intensity Test: This test determines the energy output of the UV lamp’s sufficiency in killing the microorganisms within the cabinet’s work zone. 70% ethanol shall be used to clean the surface of the bulb prior to performing the test. To carry out the test, UV radiation intensity meter shall be used to obtain light intensity at work surface level within the cabinet. UV Radiation intensity inside the cabinet should not be less than 40 μW/cm2 at 254 nanometers (nm).

Containment Test using KI Discus Method: The KI (potassium iodide) discus test is defined in the European Standard for microbiological safety cabinets, EN12469, as a test method for validating the operator protection capabilities of the cabinet. The KI Discus test has been designed to enable operator protection factors to be measured for class I and Class II open fronted biological safety cabinets. Unlike test methods employing a microbiological aerosol challenge this technique enables cabinets to be evaluated without the risk of microbial contamination of either the biological safety cabinet or the laboratory.

The selection and use of Biological Safety Cabinets (BSCs) are not merely technical choices but essential components of ensuring safety, compliance, and operational efficiency in laboratory environments. By understanding the classifications, regulatory standards, and specific application needs, organizations can effectively mitigate risks to personnel, products, and the environment. Whether for research, clinical diagnostics, or industrial applications, the right BSC not only safeguards work but also underscores a commitment to best practices in biosafety and quality assurance.

Here, we explore the key aspects of developing a robust regulatory strategy, with a focus on using proper terminology that aligns with global regulatory expectations.

Understand Regulatory Classifications

The first step in your regulatory strategy is to accurately classify your device. This requires using correct and precise terms, as these determine the regulatory requirements your product must meet.

• Novel Devices: Products with no predicate or existing equivalent in the market. Highlight features that are first-of-its-kind while ensuring clear descriptions of their intended use.

• New Devices: Devices that are introduced with incremental improvements or new indications for use, but with a predicate device available for comparison.

• Next-Generation Devices: Products with significant advancements in technology or functionality, often building on the performance of earlier iterations.

Correct classification helps define the applicable regulatory pathway, whether it's a 510(k) submission, PMA (Premarket Approval), or a De Novo classification for U.S. FDA, or CE marking under MDR for the EU or New Device Approval under CDSCO by Clinical Investigation.

Adopt Standardized Terminology in Submissions

Regulatory bodies expect consistent, standardized terminology to describe device functions, mechanisms, and benefits. Using terms from international standards such as ISO 13485 and IEC 60601 ensures clarity and conformity. Examples include:

• For IVDs, refer to terms in ISO 20916 for performance evaluation.

• Use harmonized symbols and terms recognized in ISO 15223-1 for labeling.

• Clearly differentiate between diagnostic, screening, and monitoring in IVD device descriptions.

How and When use to use Novel, New, and Next-Generation for your device

Choosing the correct term—Novel, New, or Next-Generation—to describe your medical or in vitro diagnostic (IVD) device is crucial for regulatory submissions, marketing materials, and stakeholder communication. Misusing these terms can lead to misunderstandings or delays in regulatory approvals. Below is a guide to understanding and applying these terms appropriately.

1. Working Principle

Definition:
The working principle of a medical or IVD device describes the fundamental scientific or engineering concept underlying its functionality. This provides the theoretical foundation that explains how the device achieves its intended purpose.

Example in Medical Devices:

• The working principle of an MRI scanner is based on nuclear magnetic resonance (NMR), where hydrogen atoms in the body align with a magnetic field and emit signals used to construct detailed internal images.
  Example in IVD Devices:

• The working principle of an ELISA test relies on the interaction between antigens and antibodies, with a detectable enzymatic reaction signaling the presence of the target analyte.

2. Principle of Operation

Definition:
The principle of operation describes how the working principle is applied in practice through the design and functionality of the device. It outlines the steps or mechanisms the device uses to execute its intended purpose.

Example in Medical Devices:

• In an infusion pump, the principle of operation includes using a peristaltic mechanism to deliver a precise volume of fluid to the patient at a controlled rate.
  Example in IVD Devices:

• For a PCR device, the principle of operation includes thermal cycling to amplify DNA, followed by real-time fluorescence detection of amplified sequences. 

3. Mechanism of Action

Definition:
Often used interchangeably with working principle, this term is more common when discussing therapeutic or diagnostic agents. It refers to how the device or drug interacts with biological systems to achieve its effect.

Example:

• The mechanism of action of a pacemaker involves delivering electrical impulses to the heart to regulate its rhythm.

4. Mode of Action

Definition:
This term is specifically used in regulatory contexts to describe the primary means by which a device achieves its therapeutic or diagnostic effect. It is crucial for classification and regulatory approval.

Example:

• A mechanical ventilator’s mode of action is classified as providing respiratory support through controlled airflow to the lungs.

5. Intended Use vs. Indications for Use

Intended Use:
Defines the general purpose of the device, specifying what it is meant to do.
Example:

• A blood glucose meter’s intended use is to measure blood glucose levels in diabetic patients.

Indications for Use:
Outlines the specific medical conditions, patient populations, or clinical scenarios the device is designed for.
Example:

• A blood glucose meter is indicated for diabetic patients requiring regular glucose monitoring.

6. Key Supporting Terms

Functionality

Describes the specific tasks or outputs a device performs, highlighting its operational capabilities.
Example:

• The functionality of a pulse oximeter is to measure oxygen saturation and pulse rate.

Technical Specifications

Provides the measurable parameters and features that define a device’s operational limits and capabilities.
Example:

• For a CT scanner, specifications include slice thickness, spatial resolution, and radiation dose.

Clinical Performance

Refers to the effectiveness and safety of a device in actual clinical use, often validated through trials or post-market surveillance.
Example:

• The clinical performance of an IVD test kit is assessed by sensitivity, specificity, and reproducibility metrics.

Application in Documentation

When documenting for medical and IVD devices, these terms are typically detailed in:

• Technical Files or Design Dossiers (for regulatory submission).

• User Manuals (for end-user guidance).

• Clinical Evaluation Reports (to validate safety and performance).

Novel Devices typically disrupt existing paradigms, requiring new regulatory pathways, extensive clinical testing, and potential reclassification efforts.

New Devices build on existing frameworks but introduce significant updates or address unmet clinical needs.

Next-Generation Devices refine the usability andperformance of established technologies, offering incremental yet impactful improvements.

Align with Global Regulatory Frameworks

Each regulatory body has specific terminologies and requirements:

• FDA: Focuses on "substantial equivalence" for new devices under 510(k). Clearly define terms like "clinical benefit," "real-world evidence," and "innovative technology."

• EU MDR/IVDR: Emphasizes “state of the art” and “scientific validity.” Use terms aligned with these regulations to describe device functionality and intended use.

• WHO Prequalification: For global IVD distribution, align terms like “public health need” and “assay performance” with WHO guidelines.

Regulatory Pathway Examples

• Novel Devices: Require a de novo classification (e.g., FDA De Novo) or PMA due to the absence of predicates.
• New Devices: Can often leverage existing regulatory pathways like the 510(k) or EU MDR Class IIa/IIb route, Notified Device approval (CDSCO).
• Next-Generation Devices: Typically follow existing pathways but may need additional evidence to demonstrate improved safety or performance.

• For novel devices, define unmet clinical needs and justify the device's innovative claims.
• For next-generation devices, focus on how advancements improve patient outcomes or reduce risks.
• For new devices, highlight iterative changes while showing alignment with existing regulatory frameworks.

Historical Context of Device Classification

The FDA’s regulatory framework for medical devices was established with the Medical Device Amendments of May 28, 1976. These amendments, under Section 201(h) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), laid the groundwork for device classification by:

• Defining a medical device as any product achieving its purpose without chemical action or metabolization.
• Introducing three risk-based classes (I, II, and III) to categorize devices.
• Implementing general and special controls tailored to the level of risk.

By the mid-1980s, initial classification efforts were completed, providing a foundation for regulatory oversight.

Understanding the Three Device Classes

Class I: General Controls

Class I devices represent the lowest risk and are subject to the least stringent regulatory controls. These devices generally require:

• Establishment registration and electronic device listing.
• Adherence to labeling requirements.
• Compliance with Quality System regulations.

Examples: Adhesive bandages, IV stands, and sunglasses.

Class II: General and Special Controls

Devices in Class II pose moderate risk, requiring both general and special controls to ensure safety and effectiveness. Special controls may include:

• Specific labeling requirements.
• Mandatory performance standards.
• FDA-issued guidelines.

Examples: Syringes, surgical masks, and powered wheelchairs.

Class III: Premarket Approval (PMA)

Class III encompasses high-risk devices that support or sustain human life or present potential risks if malfunctioning. These devices require rigorous premarket approval and comprehensive safety data.

Examples: Heart valves and implantable neuromuscular stimulators.

Key Classification Categories

Preamendments Devices

These devices were commercially available before May 28, 1976, and include Class III devices requiring PMA after the FDA’s regulatory publication.

Postamendments Devices

Introduced after May 28, 1976, these devices default to Class III until classified by the FDA, with requirements similar to preamendments devices.

Transitional Devices

Originally regulated as drugs before 1976, these devices (e.g., intraocular lenses) have transitioned to device regulation, often requiring PMA unless reclassified.

Addressing New Devices: The De Novo Pathway

Innovative devices not fitting into existing classifications default to Class III. However, the FDA’s De Novo process provides a pathway to classify low-to-moderate-risk devices into Class I or II based on a risk-based strategy. Once classified:

• The device is legally marketed.
• It establishes a new regulatory classification, serving as a predicate for future similar devices.

Navigating Premarket Submission Processes

Understanding the different premarket submission pathways is crucial for device manufacturers. Key submission types include:

1. Premarket Notification [510(k)]: Required for devices demonstrating substantial equivalence to a legally marketed device.
2. Premarket Approval (PMA): Necessary for Class III devices, requiring scientific evidence of safety and effectiveness.
3. De Novo Classification Request: A pathway for novel devices to achieve Class I or II classification based on risk assessment.
4. Humanitarian Device Exemption (HDE): For devices intended to treat rare diseases or conditions affecting fewer than 8,000 individuals annually in the U.S.

Importance of Proper Classification

Accurate classification determines the regulatory controls applicable to a device, streamlining compliance and market access. Essential tools and resources include:

• The FDA’s Product Classification Database for identifying device classifications.
• CDRH Learn and Device Advice platforms for regulatory guidance.

General and Special Controls in Focus

• General Controls: These apply universally across all device classes, covering aspects like labeling, premarket notification, and adverse event reporting.
• Special Controls: These are device-specific and may include performance standards, post-market surveillance, or additional labeling requirements.

Exploring Risk-Based Regulatory Strategies

The FDA’s risk-based approach ensures that regulatory scrutiny aligns with the potential risks associated with a device. Key principles include:

1. Risk Categorization: Assigning devices to Class I, II, or III based on intended use, risk level, and technological characteristics.
2. Post-Market Requirements: Implementing controls like adverse event reporting and quality system audits to maintain device safety after approval.

Leveraging FDA Resources

The FDA provides multiple educational tools to assist manufacturers and stakeholders:

1. CDRH Learn: Multi-media educational modules covering regulatory topics.
2. Device Advice: Comprehensive text-based guidance.
3. Division of Industry and Consumer Education (DICE): A direct support service for regulatory queries.

Adapting to Regulatory Updates

Manufacturers must stay updated with evolving FDA guidelines and regulatory changes. Regular engagement with FDA resources and industry training programs ensures compliance and helps address emerging challenges.

The FDA’s device classification system is a cornerstone of medical device regulation, ensuring that devices are evaluated based on risk and intended use. By understanding this framework and leveraging available resources, manufacturers can navigate the regulatory landscape effectively, ensuring their products meet safety and efficacy standards.

Acknowledgment

This article is adapted from the Device Classification Overview by William M. Sutton, Deputy Director of the Division of Industry and Consumer Education at the FDA, presented during the 2015 REdI (Regulatory Education for Industry) conference.

Access the guidance 👇

Scope of the ISO 13485 Standard

ISO 13485, "Quality Management System - Requirements for Regulatory Purposes," begins with Clause 1, titled "Scope." This clause outlines the situations where the standard's requirements apply to an organization. In general, the full scope of ISO 13485 applies to your QMS unless specific activities are not performed by your organization. For example, exemptions may include:

• Clause 7.3 (Design and Development) if your organization does not engage in product design.
• Calibration of measuring equipment if your organization does not use such equipment.
• Clauses relating to sterilization activities or implantable devices if these are not relevant.

Example for IVD and Medical Devices:

For an in-vitro diagnostic (IVD) company that only manufactures test kits and does not design products, Clause 7.3 could be excluded. Similarly, a medical device manufacturer focusing on non-sterile devices may not need to comply with clauses related to sterilization.

Scope of the Management System

Defining the scope of your management system involves identifying the parts of your business included within the QMS. This must be documented, often in a concise paragraph. The scope should clearly outline the boundaries and responsibilities, ensuring no critical areas are arbitrarily excluded. If an area outside the QMS impacts quality, it must still be controlled, similar to an external provider.

While determining the scope of your QMS, it is essential to include conformity related to processes, organizational activities, services, and products offered by the organization. This ensures the QMS comprehensively covers all aspects affecting quality. Avoid overly broad statements, such as "manufacturing Class I and II devices," as these lack specificity. Instead, detail the activities and categories of devices covered within the QMS.

Examples of QMS Scope:

1. Specific Scope: "Design, manufacture, and distribution of diagnostic imaging devices and accessories for healthcare applications."
2. Focused Scope: "Production and testing of IVD reagents for clinical laboratories."
3. Precise Scope: "Manufacture and packaging of orthopedic surgical instruments for global distribution."

Key Considerations:

• Customer expectations: For example, excluding R&D might be acceptable if your customers are not concerned about design capabilities. However, excluding critical production steps would likely raise concerns.
• Strategic decisions: Determining the scope is a strategic task for top management, often influenced by customer and regulatory needs.

Scope of the Certification

The scope of certification is usually aligned with the management system's scope but can sometimes be narrower. This scope is displayed on the ISO 13485 certificate and must provide a clear description of the covered products, services, and activities.

It is important to note that the product certification scope pertains specifically to the conformity of products in terms of their quality and efficacy. While a QMS scope addresses broader organizational aspects, a product certification scope focuses solely on verifying product performance against specified standards.

Examples of Certification Scope Statements:

Any changes to the scope of certification typically require an external audit. Many organizations prefer to adjust their scope during scheduled surveillance or recertification audits.

Audit Scope

The audit scope defines the locations and activities an auditor will review. For external audits, this scope matches the certification scope. For internal audits, the organization has flexibility. Internal audits can focus on specific requirements, locations, or processes at different times.

Tips for Internal Audits:

• Use a risk-based approach to prioritize high-impact areas.
• Ensure coverage over time to maintain compliance across all QMS elements.

Practical Application: Determining Your Organization's Scope

In most cases, the QMS scope covers the entire organization. However, exceptions occur, such as:

1. When the QMS applies to only one location within a multi-location company.
2. When manufacturing or service operations are distinctly split between industries.

Examples:

• Medical Device Manufacturer: "Design and assembly of diagnostic imaging devices and related accessories for healthcare applications."
• IVD Distributor: "Distribution and warehousing of clinical laboratory diagnostic kits."
• Surgical Instrument Manufacturer: "Manufacture and sterilization of Class II orthopedic surgical instruments."

Crafting a Clear Scope Statement

Your scope statement should:

1. Be concise yet detailed enough to clarify what is covered.
2. Include the activities, relevant products or services, and applicable categories of devices.
3. Clearly indicate any exclusions.

Example Statements:

Periodic Review of Your QMS Scope

Regularly revisiting your QMS scope ensures alignment with evolving organizational objectives and regulatory landscapes. Organizations should leverage internal audits and stakeholder feedback to maintain an effective and compliant QMS.

A well-defined scope prevents ambiguity and aligns your QMS with organizational goals, customer needs, and regulatory requirements. It also simplifies audits and certifications, ensuring a smooth path to compliance with ISO 13485.

Temporary Licenses

Temporary licenses are primarily issued for research and validation purposes. These licenses enable the development and evaluation of medical devices and investigational products. They are critical for fostering innovation and ensuring the safety and efficacy of devices before market introduction. These licenses are non-renewable and only valid for purpose granted, their validity is not extended in any circumstances.

Key Types:

• Test Licenses:
• Purpose: For testing and evaluation of medical devices, including performance evaluations of IVDs and clinical investigations.
• Regulatory Form: Form MD-12, MD-16
• Clinical Investigation Permissions:
• Purpose: To conduct clinical investigations for high-risk devices (Class C and D).
• Regulatory Form: Form MD-22, MD-24
• Manufacturing Permission for Investigational Devices:
• Purpose: For manufacturing devices intended for use in clinical investigations.
• Regulatory Form: MD-26, MD-28

Commercial licenses are intended for entities involved in the production, sale, and distribution of medical devices. These licenses ensure that the devices marketed in India meet established safety, quality, and performance standards. These licenses can be renewed and subject to perpetuity of the fees paid.

Key Types:

• Manufacturing License:
• Purpose: For manufacturing medical devices intended for sale and distribution.
• Applicable Classes: Class A, B, and Class C, D.
• Regulatory Form: Form MD-3 for Class A and B devices; Form MD-7 for Class C and D devices.
• Requirements:
• A valid Quality Management System (QMS) in compliance with ISO 13485.
• Defined manufacturing site with qualified personnel and equipment.
• Wholesale License:
• Purpose: For entities engaged in the wholesale distribution of medical devices.
• Regulatory Authority: State Licensing Authority (SLA).
• Regulatory Form: MD-41
• Loan License:
• Purpose: For manufacturers who use the facilities of another licensed manufacturer to produce medical devices.
• Regulatory Form: Form MD-4 for Class A and B; Form MD-8 for Class C and D.
• Requirements:
• An agreement between the original and loan license holder.
• Compliance with ISO 13485 standards.

• Import License:

• Purpose: For businesses importing medical devices into India.
• Applicable Classes: All classes (A, B, C, D).
• Regulatory Form: Form MD-15 (application for import license).
• Requirements:
  • Device registration in Form MD-14.
  • Importer’s authorization from the manufacturer.
  • Certificate of Free Sale from the country of origin.
  • Declaration of conformity to Indian standards, where applicable.

The Medical Device Rules 2017 have established a comprehensive licensing framework to cater to both research and commercial needs in the medical device sector. Temporary licenses facilitate innovation by supporting research and validation, while commercial licenses ensure the quality and safety of devices intended for public use. Understanding these categories and their specific requirements is critical for businesses to navigate the regulatory landscape and achieve compliance with Indian regulations.

What Are Vaginal Tampons?

Vaginal tampons are small, cylindrical products made from absorbent materials such as cotton or rayon. They are designed to be inserted into the vagina to collect menstrual blood before it leaves the body. Unlike external pads, tampons are worn internally, offering discreet and comfortable protection throughout the day.

Key Points About Vaginal Tampons:

• Function: Absorb menstrual blood.
• Material: Made primarily of cotton or rayon fibers.
• Application: Inserted into the vagina, often with an applicator.
• Usage Tips: Choose the appropriate size based on menstrual flow, ensure proper insertion, and change tampons regularly to prevent infection.

Purpose of the Literature Review

The review aimed to assess existing evidence on contaminants found in tampons and their potential health effects. Nine published articles were analyzed, focusing on a variety of contaminants, including:

• Metals
• Phthalates
• Parabens
• Bisphenols
• Volatile Organic Compounds (VOCs)
• Dioxins
• Triclocarban

Key Findings:

While limitations were noted in the study methodologies, no evidence suggested that contaminants identified in tampons were released into the body or absorbed through the vaginal lining. Based on the available data, the FDA reaffirms that tampons remain a safe menstrual product option.

Additional Research Underway

The FDA is conducting its own laboratory study to assess whether metals present in tampon materials are released or absorbed by the body during normal use. This study is designed to simulate real-life conditions and will measure:

• The amount of metals released from tampon materials.
• Potential absorption of these metals into the body.

Once completed and peer-reviewed, the findings will contribute to a comprehensive risk assessment of metal exposure from tampons.

FDA Actions and Commitment to Safety

The FDA initiated further evaluations after an external study published in 2024 reported low levels of metals in tampons during laboratory testing. However, that study did not examine whether the metals were released during use or absorbed by the body. To address these gaps, the FDA is undertaking additional testing to provide a more accurate assessment of potential risks.

Regulatory Oversight for Tampons

Before tampons can be sold in the United States, they must comply with stringent FDA safety and effectiveness requirements. Manufacturers are obligated to:

• Test tampon materials at various stages of production.
• Conduct biocompatibility and other safety evaluations.
• Submit these test results to the FDA for review prior to market authorization.

Contaminants in Vaginal Tampons: A Systematic Literature Review (SLR) 👇

Definition of Loan License

As per the D&C Act and Medical Device Rules, a Loan License refers to a license granted to an applicant who intends to manufacture medical devices at a premise that is already licensed to another entity. The applicant does not own the facility but utilizes it under a formal agreement with the existing licensed manufacturer.

Meaning and Purpose of Loan License

A Loan License allows an entity to legally manufacture medical devices without establishing its own production facility. It is an ideal solution for:

• Startups and small businesses looking to enter the market without heavy infrastructure investment.
• Companies with limited resources that prefer outsourcing manufacturing.
• Foreign manufacturers aiming to produce medical devices in India without setting up a local plant.
• Existing manufacturers looking to expand their product portfolio without additional capital expenditure.

When Should a Stakeholder Opt for a Loan License?

• No Own Manufacturing Facility: When a company does not have its own infrastructure but wants to manufacture medical devices.
• Cost-Effective Strategy: To avoid high capital costs associated with establishing a new manufacturing unit.
• Regulatory Compliance Ease: When utilizing an already compliant and approved facility helps in faster product approvals.
• Market Entry Strategy: When a foreign company wants to enter the Indian market without setting up its own plant.
• Expansion of Product Line: When a company wants to diversify its product offerings without modifying or expanding its existing facility.

Conditions for Obtaining a Loan License

• Valid Agreement with a Licensed Manufacturer: The applicant must have a formal agreement with an existing licensed manufacturer who owns the production facility.
• Application to the Licensing Authority: The applicant must submit an application in the prescribed format (as per MDR 2017) to the appropriate licensing authority.
• Compliance with QMS and Quality Standards: The facility must comply with the Good Manufacturing Practices outlined in the Quality Management System under ISO 13485.
• Approval of Product and Labeling Requirements: The products to be manufactured must comply with the labeling and regulatory approval norms.
• Regular Inspections and Audits: The licensed facility must be open to periodic inspections to ensure compliance with regulatory norms.

Objectives Behind the Loan License Concept

• Encouraging Small and Medium Enterprises (SMEs): Allowing businesses to operate without the burden of high capital investments.
• Fostering Contract Manufacturing: Promoting a business model where experienced manufacturers can produce devices on behalf of other stakeholders.
• Regulatory Control: Ensuring that all medical devices manufactured under a Loan License comply with safety and quality regulations.
• Facilitating Market Growth: Providing an entry pathway for startups and foreign manufacturers into the Indian market.
• Ensuring Product Availability: Meeting market demand by allowing more players to produce devices without setting up new facilities.

The Loan License provision under the D&C Act and Medical Device Rules serves as a crucial regulatory tool that enables companies to manufacture medical devices at approved facilities without having to invest in infrastructure. It is a strategic option for businesses looking to enter or expand within the Indian medical device industry while ensuring regulatory compliance and cost-effectiveness. Stakeholders must carefully assess their requirements, ensure compliance with applicable regulations, and establish a clear agreement with the licensed manufacturer before applying for a Loan License.

The field of microfluidics, which involves the precise manipulation of fluids at the microscale, has emerged as a transformative technology in diagnostics, biomedical research, and lab-on-a-chip applications. However, despite its vast potential, transitioning a microfluidic innovation from prototype to a commercially viable product remains a formidable challenge. To address this, an Expert forum was organized by Chandigarh based conference organizer Glostem Private Limited on February 28, 2025, in Hyderabad. The Expert forum was entitled “Commercializing Microfluidic-based Devices – Prototype to Product: Issues, Bottlenecks, and Solutions” This forum brought together distinguished scientist and professionals from industry and academia. The Expert forum was chaired by Amit Asthana (NIPER, Hyderabad) and Co-Chaired by Muthuraman Swaminathan (INFAB Semiconductor Pvt Ltd). The distinguished expert speakers included Dhananjaya Dendukuri (Achira Labs), Sanjiban Chakrabarty (Manipal School of Life Sciences, MAHE), Gautam Singh Rathore (QVC Certifications Services Pvt. Ltd.), Rahul Singh (Sciverse Solutions Pvt. Ltd.), Jobin Vijayan (Bit4Tech), Ajay Kumar Singh (CSIR-IICT, Hyderabad), Vijaya Bhaskar Reddy Anugu (UR Advanced Therapeutics), Rohan Aggarwal (Vidcare), and Avisek Barla (Avay Biosciences Private Limited). The forum also featured two panelists Rachana Tripathi (Huwel Lifesciences) and Manjunath Siddaramaiah (Cytiva), who shared their insights in the panel discussion entitled “The Future of Microfluidic-Based Medical Devices.” This event served as a collaborative platform to accelerate the journey from innovation to market, fostering discussions that helped navigate the complex landscape of microfluidic device commercialization. A highlight of this forum was the Medical Devices Young Innovator Award 2025, an initiative designed by Glostem to recognize and celebrate the groundbreaking contributions of young researchers and innovators in this field. “We were thrilled to provide a platform for these bright minds to showcase their work providing fresh perspectives to our discussions.” The winner was given a memento by Glostem, and a cash prize sponsored by INFAB.

Microfluidic POC Equipment Types

• Microfluidic equipment made of PDMS: These devices are fabricated using soft lithography and are significant due to the versatility and biocompatibility of PDMS polymer.
• Paper-based microfluidic devices: Fabricated using patterning technology, paper chips offer a fast and inexpensive platform for disease diagnosis and treatment.
• 3D-printed microfluidic devices: 3D printing technology enables rapid prototyping and customization of microfluidic devices, accelerating research and development efforts.
• Mobile sensors based on integrated microfluidic devices and smartphones: These integrated systems leverage the data processing and imaging capabilities of smartphones for POC detection.
• Handheld centrifugal microfluidic devices: These devices utilize centrifugal forces for fluid manipulation and offer new possibilities for electricity-free POC diagnostics.
• Microfluidic POC devices using DEP technology: Dielectrophoresis (DEP) technology enables manipulation and separation of particles based on their dielectric properties, offering potential for advanced POC applications.

Applications and Benefits of Microfluidic Devices

Microfluidic devices offer several advantages over traditional diagnostic systems:

• Small Sample Size: Enables testing with minimal fluid volumes, reducing waste and costs.
• High Speed and Efficiency: Parallel processing allows rapid diagnosis and high-throughput screening.
• Enhanced Data Quality: Offers precise control over experimental parameters, improving reproducibility and reliability.

Notable Applications:

• Detection of infectious diseases such as COVID-19, HIV, and malaria.
• Environmental monitoring for detecting contaminants.
• Drug discovery and development through lab-on-a-chip technologies.
• Personalized medicine by integrating POC testing with smart technologies like artificial intelligence (AI) and the Internet of Things (IoT).

Regulatory Landscape: Challenges and Compliance

Global Regulatory Overview

Microfluidic diagnostic devices fall under the regulatory purview of various international agencies:

• United States: The FDA regulates these devices under the Center for Devices and Radiological Health (CDRH). Device classification follows a risk-based approach: Class I (low risk), Class II (moderate risk), and Class III (high risk).
• European Union: The In Vitro Diagnostic Regulation (IVDR) classifies devices into risk categories A-D, with Class D representing the highest risk.
• India: Governed under the Medical Device Rules, 2017, requiring compliance with the Site Master File, Device Master File, risk analysis, and post-market surveillance requirements.

Key Regulatory Hurdles

• Lack of Specific Guidelines: Regulatory frameworks for microfluidic devices are evolving, with few standardized evaluation criteria.
• Validation Complexity: Microfluidic-based diagnostic devices must demonstrate analytical, clinical, and scientific validity.
• Material and Manufacturing Constraints: Scaling up production while ensuring compliance with material biocompatibility standards remains a challenge.
• Post-Market Surveillance: Continuous monitoring of device performance is required to meet stringent regulatory expectations.

Technological Advancements in Microfluidic Devices

Microfluidic technology has witnessed remarkable advancements in recent years, leading to improved performance, reduced costs, and expanded applications. These advancements have been driven by innovations in materials, fabrication techniques, and manufacturing methods.

Materials and Fabrication Techniques

Fabrication Methods

Various fabrication methods are employed in the production of microfluidic devices, each offering distinct advantages and limitations. Photolithography is a widely used technique known for its high resolution and precise patterning. However, it is an expensive process that involves complex steps, making it less accessible for low-cost applications. Inkjet printing is an emerging method that allows rapid and large-scale fabrication, but it requires specialized inks and a heating step for optimal results. Laser cutting is a fast and cost-effective approach, ideal for rapid prototyping, though it demands specialized equipment. Meanwhile, screen printing is a cost-effective solution for mass production, but it comes with the trade-off of lower resolution and the need for individual screens for each design.

The choice of fabrication method depends on factors such as precision requirements, production scale, cost constraints, and material compatibility. As microfluidic technology advances, newer and more efficient fabrication techniques continue to enhance the field, making these devices more accessible and effective for diverse applications.

This article explores the importance of standards, their applicability, and how to differentiate between certifiable and non-certifiable standards.

What Are Standards?

A standard is a set of agreed-upon guidelines, specifications, or best practices developed by recognized bodies to ensure consistency, safety, quality, and efficiency. Standards can be international, national, or industry-specific, and they are used to regulate processes, materials, services, and products.

Types of Standards

Standards can be classified into different categories based on their purpose and applicability:

• Product Standards – Define requirements for physical goods (e.g.,  IEC 60601-1-25, IEC 60601-1-45).
• Process Standards – Focus on production and operational processes (e.g., ISO 14937, ISO 15001).
• Service Standards – Ensure quality in service delivery (e.g., ISO 20000 for IT service management, ).
• Management System Standards – Provide a framework for business operations and compliance (e.g., ISO 13485 for medical devices, ISO 9001 for quality management systems, ISO 14001 for environmental management).

Certifiable vs. Non-Certifiable Standards

Not all standards require certification. Understanding the difference helps businesses determine which standards they need to comply with.

Certifiable Standards

These are standards for which organizations can obtain official certification through third-party audits. Certification proves compliance and builds credibility. These are legally required standards enforced by governments or regulatory bodies. Non-compliance may result in legal penalties, product recalls, or restricted market access.

Examples of Certifiable Standards:

• ISO 9001 (Quality Management System)
• ISO 14001 (Environmental Management System)
• ISO 27001 (Information Security Management System)
• ISO 45001 (Occupational Health and Safety)

To obtain certification, organizations must undergo an audit by an accredited certification body.

• ISO 13485 – Mandatory for medical devices in many countries (e.g., EU MDR, India’s CDSCO).
• IEC 60601-1 – Required for electrical safety of medical devices.
• Good Manufacturing Practices (GMP) – Enforced by FDA, WHO, CDSCO for pharmaceuticals and medical devices.
• 21 CFR Part 820 (QSR) – U.S. FDA-mandated quality system regulations for medical devices.
• IS 15885 / IS 16102 – Mandatory for LED lighting products in India under BIS certification.

Implementation: Companies must undergo regulatory audits, submit technical documentation, and receive official approval from relevant authorities.

 Non-Certifiable Standards

These standards serve as guidelines or best practices but do not have a formal certification process. Organizations can adopt them voluntarily to improve operations. These are not legally required but widely adopted to demonstrate quality, efficiency, and competitiveness. They can be certifiable (allowing third-party certification) or non-certifiable (guidelines for best practices).

Examples of Non-Certifiable Standards:

• ISO 26000 (Social Responsibility)
• ISO 31000 (Risk Management)
• ISO 19011 (Guidelines for Auditing Management Systems)

Though non-certifiable, these standards are widely used to improve governance, risk management, and corporate responsibility. The standards which are meant for the adoption or enhancement of the process are majorly non-certifiable. Any standard which sets specification of any product is non certifiable until unless mandated by the Regulatory or Government Authority to be verified by the Laboratory established under any rules.

Which Standards Are Certifiable by Accredited Bodies?

Accreditation bodies certify testing and certification bodies only for specific types of standards, not all standards. The certifiability of a standard depends on whether it meets the criteria for third-party conformity assessment and aligns with recognized accreditation schemes.

Management System Standards (Certifiable)

Accreditation bodies grant certification for Management System Standards that require organizations to establish, implement, and maintain structured processes.

 Examples of Certifiable Management System Standards:

• ISO 9001 – Quality Management System (QMS)
• ISO 13485 – Medical Devices Quality Management System (MD QMS)
• ISO 14001 – Environmental Management System (EMS)
• ISO 45001 – Occupational Health & Safety (OHS)
• ISO 22000 – Food Safety Management System (FSMS)
• ISO 27001 – Information Security Management System (ISMS)

Non-Certifiable Management Guidelines:

• ISO 26000 – Social Responsibility (guidance only, no certification)
• ISO 31000 – Risk Management (framework, no certification)

Accreditation bodies certify products based on conformance to safety, performance, and quality requirements set by product-specific standards.

Examples of Certifiable Product Standards:

• IEC 60601-1 – Electrical Safety of Medical Devices
• BIS IS 15885 – LED Lighting Products (Bureau of Indian Standards)

Non-Certifiable Product Guidelines:

• ISO/TR 24971 – Risk Management Guidance for Medical Devices (support document, not certifiable)
• ISO 14971 – Medical Device Risk Management (linked to certification via ISO 13485)

Laboratories conducting product testing or calibration must comply with accreditation schemes under ISO/IEC 17025 or related standards.

Examples of Certifiable Testing & Calibration Standards:

• ISO/IEC 17025 – General requirements for testing and calibration labs
• ISO 15189 – Medical Laboratory Accreditation (for clinical laboratories)

Non-Certifiable Testing Guidelines:

• ISO/IEC Guide 98-3 (GUM) – Guide to the Expression of Uncertainty in Measurement (used for guidance, not certification)

Accreditation is granted to certification and inspection bodies under specific ISO standards.

Examples of Certifiable Standards for Certification/Inspection Bodies:

• ISO/IEC 17021-1 – Accreditation of management system certification bodies
• ISO/IEC 17065 – Accreditation of product certification bodies
• ISO/IEC 17020 – Accreditation of inspection bodies

Are There Guidelines for Inclusion of Standards for Accreditation?

Yes! Not all standards qualify for certifiable accreditation schemes. The accreditation body follows international guidelines to determine which standards can be included:

• The standard must include objective, measurable criteria that can be assessed and certified by a third party.
• Example: ISO 9001 has defined clauses and requirements that auditors can evaluate, making it certifiable.

• Accreditation bodies follow frameworks like IAF (International Accreditation Forum) and ILAC (International Laboratory Accreditation Cooperation) to decide which standards qualify for certification.
• Example: ISO 45001 is part of IAF’s recognized schemes, so accredited certification is possible.

• Some standards, like ISO 26000 (Social Responsibility) and ISO 31000 (Risk Management), provide guidance but lack certification mechanisms.
• These are used for self-implementation rather than third-party certification.

• Some product safety and environmental standards become certifiable only if a country’s regulatory framework requires compliance.
• Example: CE Marking (Medical Devices, IVDs, Electronics, etc.) requires conformity to specific harmonized standards for certification.

Standards are essential for ensuring quality, safety, efficiency, and market competitiveness. Whether certifiable or non-certifiable, they help organizations improve processes, comply with regulations, and gain customer trust. Identifying and implementing the right standards can drive long-term success and sustainability.

By understanding their applicability, businesses can make informed decisions on adopting and certifying standards to enhance their operations and credibility.

Not all standards are certifiable — only those that meet conformity assessment requirements and are recognized under accreditation schemes. Accreditation bodies certify management systems, products, testing laboratories, and inspection bodies based on internationally accepted criteria. However, best-practice guidelines and advisory standards cannot be certified.

The synergy between mRNA and LNPs has already proven successful—most notably in the development of COVID-19 vaccines by Pfizer-BioNTech and Moderna—and is rapidly expanding into therapeutic areas such as oncology, rare genetic diseases, and infectious diseases. However, while the promise is immense, the regulatory landscape for LNP-based mRNA therapeutics is still maturing.

The U.S. Food and Drug Administration (FDA) has acknowledged the potential of nanomedicine but also faces challenges in establishing regulatory clarity for these novel products. Key hurdles include their unique mechanism of action, complex classification under biologic and gene therapy frameworks, and the need for robust safety and manufacturing controls.

This article outlines a comprehensive regulatory strategy to navigate these challenges and achieve FDA approval. It explores classification issues, addresses regulatory and safety concerns, and provides a stepwise pathway including preclinical studies, clinical development, and expedited approval options. By understanding the regulatory nuances, developers can accelerate product development while ensuring safety, efficacy, and compliance—ultimately advancing the future of personalized medicine.

Product Classification and Regulatory Challenges for mRNA-LNP Therapeutics

Understanding the Product

Lipid nanoparticles (LNPs) are nanoscale carriers engineered from ionizable lipids, phospholipids, cholesterol, and PEG-lipids. These components work synergistically to encapsulate mRNA and facilitate its delivery into the cytoplasm of target cells. LNPs ensure that the mRNA remains stable during systemic circulation and is efficiently released upon cellular uptake. 

Key advantages of LNPs include:

• Efficient encapsulation and delivery of mRNA
• Targeted tissue distribution (e.g., liver targeting via lipid modification)
• Scalable and rapid manufacturing for outbreak response
• Reduced innate immune activation compared to other delivery methods

Their success in COVID-19 vaccines has demonstrated their therapeutic viability, but broader applications require clear regulatory strategies to address emerging complexities.

Key Regulatory Challenges

Despite significant momentum, LNP-based mRNA therapeutics face distinct regulatory hurdles:

1. Novel Mechanism of Action

Unlike conventional drugs or biologics, mRNA therapeutics function by encoding genetic instructions that trigger in vivo protein synthesis. This novel approach lacks historical regulatory precedence, especially for non-vaccine applications. As a result, existing frameworks must be adapted or redefined to accommodate safety and efficacy assessments.

Example: The Emergency Use Authorizations (EUAs) for mRNA COVID-19 vaccines required tailored regulatory adjustments. For therapeutic applications, such as mRNA-based cancer immunotherapy, FDA guidance remains in development.

Determining the regulatory pathway—whether under the Center for Biologics Evaluation and Research (CBER) or the Center for Drug Evaluation and Research (CDER)—can be complex. mRNA therapeutics often straddle biologic and gene therapy categories, complicating trial design, labeling, and post-market obligations. 

Example: BioNTech’s mRNA melanoma vaccine faced delays due to uncertainty over whether it should be reviewed as a biologic or personalized gene therapy.

Though LNPs are designed to minimize immune responses, certain formulations have shown inflammatory and hepatotoxic effects in preclinical models. Regulatory agencies require comprehensive safety profiling, including cytokine release assessments and immunotoxicity studies.

Example: Some LNP formulations used in preclinical gene therapies led to elevated liver enzymes and systemic inflammation, raising red flags for early human trials.

 4. Chemistry, Manufacturing, and Controls (CMC) Complexity

Case in Point: Moderna’s mRNA-1273 vaccine received Fast Track, Breakthrough Therapy, and Priority Review designation during development—a model that may inform future therapeutic approvals.

Strategic Considerations for Developer-FDA Interactions

Proactive and transparent communication with the FDA is vital. Consider these best practices:

🔄 Insight: A platform-based regulatory strategy—where similar LNP formulations are used for multiple mRNA payloads—can streamline future INDs and reduce redundancy in CMC submissions.

LNP-based mRNA therapeutics hold immense potential across a wide range of diseases, offering precise, rapid, and scalable treatment options. However, realizing this potential requires a clear, forward-looking regulatory strategy that addresses the complexities of classification, safety, manufacturing, and global distribution.

By adopting a proactive approach—built on early FDA engagement, rigorous CMC planning, and strategic use of expedited pathways—developers can accelerate time-to-market without compromising on safety or quality. As regulatory science evolves, particularly in response to the success of mRNA vaccines, the future is promising for therapeutic applications.

✅ With the right strategy, LNP-mRNA therapeutics can move from bench to bedside—ushering in a new era of personalized, RNA-based medicine.

A key aspect of risk management is quantifying risk, which helps manufacturers take appropriate actions to mitigate potential hazards. One of the most commonly used methods for quantifying risk is through the Risk Priority Number (RPN).

What is Risk Priority Number (RPN)?

The Risk Priority Number (RPN) is a numerical score used to quantify and prioritize risks associated with potential failure modes in a product, process, or system. It is most prominently used in Failure Modes and Effects Analysis (FMEA), but it is also a foundational tool across a wide range of risk management techniques and quality improvement methodologies.

Techniques and Methodologies Where RPN is Used

• Design FMEA (DFMEA): Used in product design to anticipate potential design-related failures.
• Process FMEA (PFMEA): Used to evaluate failures that may occur during manufacturing or operational processes.
• Software FMEA: Applied in medical device and IT systems to assess software failures and potential effects on users.
• Service FMEA: Adopted in healthcare, logistics, and customer service industries to improve service delivery and prevent failures.
• Maintenance FMEA: Used in predictive and preventive maintenance planning to reduce equipment failures.
• Hazard Analysis and Critical Control Points (HACCP): In food safety and pharma, RPN can be adapted to prioritize hazards based on risk levels.
• Risk-Based Inspection (RBI): In asset integrity management, RPN helps determine inspection priorities based on risk.
• Root Cause Analysis (RCA): Used post-failure to prioritize corrective actions based on risk impact using RPN scoring.
• APQP & PPAP (Automotive Standards): RPN is embedded in FMEA steps within Advanced Product Quality Planning and Production Part Approval Process.

How is RPN Determined?

The Risk Priority Number (RPN) is calculated using the formula:

RPN=Severity (S)×Occurrence (O)×Detection (D)

Each factor is rated on a scale—commonly 1 (low risk) to 10 (high risk):

• Severity (S): The impact of the failure if it occurs.
• Occurrence (O): The probability of the failure happening.
• Detection (D): The likelihood that the failure will be detected before it causes harm or escapes to the customer.

This traditional method provides a quantitative risk score ranging from 1 to 1000, with higher values indicating more critical risks.

While the traditional RPN method provides a numerical approach to prioritize risks, it fails to account for specific risk scenarios where the combination of factors does not reflect the real-world criticality of the hazard. Here are key limitations and exceptions:

Exception 1: High Severity + Low Occurrence = Still Intolerable (INT)

Problem:
RPN may yield a low or moderate score if occurrence is rare—even if severity is catastrophic.

Example:

• Severity = 10 (Death or serious harm)
• Occurrence = 1 (Rare)
• Detection = 2 (Likely to detect)
• RPN = 10 × 1 × 2 = 20 (Looks low!)

Resolution in Matrix Methods:
In risk matrices (like ISO 14971 or medical device QRM), this would still be classified as Intolerable (INT) due to high severity—regardless of RPN score.

Exception 2: Catastrophic Hazard = Always INT (Irrespective of Matrix Output)

Problem:
A hazard identified as catastrophic (e.g., causing death, systemic failure) cannot be tolerated under any condition.

Resolution:
Matrix-based approaches include a rule override, ensuring that:

If the hazard is catastrophic, the risk is automatically “Intolerable,” even if RPN or matrix combination indicates Acceptable (BA) or ALARP.

Exception 3: Critical Hazards ≠ BA (Broadly Acceptable)

Problem:
Even when RPN is low, a critical-level hazard (e.g., failure of life support) should not be marked “Acceptable” without mitigation.

Resolution:
Policy-driven matrices define:

If the hazard is critical, the evaluation can be at best “ALARP” (As Low As Reasonably Practicable), not “BA.”

This ensures that critical risks are never overlooked by misleading low RPN scores.

Policy Integration Example

In organization’s Risk Management Policy, can define:

• “All hazards rated as Catastrophic will be classified as Intolerable regardless of RPN.”
• “Risks with Severity ≥ 9 and Occurrence ≤ 2 must be reviewed by the Risk Committee before acceptance.”
• “Critical risks must be at least ALARP; no BA ratings allowed.”

These rules provide safeguards and prevent misclassification due to RPN scoring artifacts.

How RPN Calculation Supports Risk Policy in an Organization

An organizational risk policy outlines how risks are identified, evaluated, mitigated, and monitored. RPN plays a crucial role in operationalizing this policy. Here's how:

1. Risk Prioritization and Thresholds

• RPN provides a measurable threshold to determine which risks are acceptable, tolerable with mitigation, or unacceptable.
• Organizations may define policy rules such as:
• RPN > 200 → Requires immediate action.
• RPN 100–200 → Needs monitoring and mitigation plan.
• RPN < 100 → May be accepted with justification.

2. Decision-Making Framework

• By comparing RPNs, companies can make consistent decisions across departments or projects.
• Avoids subjective or inconsistent risk assessment.

3. Documentation and Audit Readiness

• RPN calculations form part of a documented risk register or FMEA log, supporting compliance with regulatory frameworks like:
• ISO 13485 (Medical Devices)
• IATF 16949 (Automotive)
• FDA 21 CFR 820
• ISO 14971 (Medical Device Risk Management)

4. Risk Communication

• Risk scores help communicate the urgency and criticality of issues across functions—especially between engineering, quality, and regulatory teams.

5. Continuous Improvement

• After implementing controls, RPN can be recalculated to demonstrate risk reduction over time.
• Enables data-driven improvements to processes, designs, or systems.

6. Custom Risk Appetite Alignment

• Organizations can tailor their RPN calculation method and scoring system to align with their specific risk appetite and industry expectations.

3D Methodology for Risk Priority Number (RPN) Calculation

To overcome the critical limitations of the traditional RPN model, a new three-dimensional matrix-based methodology has been developed. This approach addresses the inconsistencies found in standard models by incorporating a reverse-check mechanism and aligning RPN evaluation with real-world impact and decision logic.

Key Concept: Three-Dimensional Risk Prioritization

Unlike the traditional RPN model (S × O × D) which is purely multiplicative and linear, the new methodology introduces a 3D matrix where:

This structure accounts for the severity as a controlling or moderating factor, rather than just a multiplier. By treating severity as a divider, the model simulates a real-world tolerance threshold—where high severity naturally suppresses risk acceptability even if other values are low.

How the Matrix Works

• 🔴 Red: Intolerable Risk
• ⚪ White: ALARP (As Low As Reasonably Practicable)
• 🟢 Green: Broadly Acceptable Risk

This setup enables bidirectional risk analysis, meaning it not only shows where a risk lies (like traditional RPN) but also whether that risk should be tolerated in context of severity thresholds.

📊 Terms Used in the Evaluation Matrix

• Probability of Occurrence (P)
• Detection/Diagnosis (D)
• Severity of Harm (S)

Depicted as:
P × D = [Matrix Value] : S

D is inversely proportional to S

P is directly proportional to S

Use in Organizational Risk Policy

This method supports policy-making and risk governance by:

• Defining clear zones of action (e.g., Red = Not Acceptable under any conditions).
• Reinforcing override rules based on severity.
• Guiding cross-functional teams in risk review meetings with unambiguous visuals.
• Allowing risk tracking and trending over time with consistency.

By replacing or complementing traditional RPN calculations with this three-dimensional matrix, organizations can improve the reliability of risk scoring, reduce underestimation of critical hazards, and support stronger decision-making in safety-critical environments.

Traditional RPN models, while widely used, often fall short in real-world applicability due to their linear nature and inability to prioritize severity appropriately. They also lack the flexibility to accommodate reverse logic scenarios, where a catastrophic event with low probability might still be deemed unacceptable.

To overcome these limitations, the 3D RPN Matrix developed by Gautam Singh Rathore introduces a three-dimensional evaluation—multiplying Probability (P) and Detectability (D) to determine a base score, and then applying a Severity (S) filter to classify risk outcomes into actionable categories.

This approach brings several advantages:

• Severity-Driven Filtering: Ensures critical hazards are never understated, regardless of detectability or occurrence.
• Reverse Evaluation Capability: Flags intolerable risks even when traditional RPN values suggest acceptability.
• Real-World Alignment: Reflects practical risk management decisions with better clarity and control.
• Visual Interpretation: Color-coded zones allow for immediate understanding and communication across teams.
• Policy Integration: Supports the development of clear, evidence-based risk thresholds that align with ISO 14971 and regulatory expectations.

Best Practices for Organizations

1. Adopt 3D RPN for Risk Evaluation in safety-critical environments (e.g., medical devices, pharma manufacturing, aviation).
2. Train risk assessors to interpret Severity as a non-negotiable filter, not just a multiplier.
3. Incorporate matrix-based visualization into risk dashboards and QMS systems.
4. Review and update risk thresholds based on evolving product use cases and post-market data.
5. Document exceptions transparently, and use data-driven thresholds to justify risk acceptability or mitigation actions.

Two of the most common methodologies used in product development are the Waterfall model and the Agile methodology. Each has distinct strengths and weaknesses, especially when applied in regulated environments. In this article, we explore how these methodologies apply to the medical and IVD sectors—and how a hybrid approach is often the most practical path forward.

Waterfall Model: Structured and Sequential

The Waterfall model follows a linear and sequential flow of activities where progress is made step by step. It’s especially well-suited for regulated product development where traceability, documentation, and formal reviews are essential.

Regulatory Fit:

• Aligns perfectly with ISO 13485 design control clauses.
• Supports FDA premarket submissions (510(k), PMA).
• Easier to audit and manage with tools like DHF, DMR, and Trace Matrix.

Limitations:

• Inflexible once in execution—iterating mid-process may mean restarting verification/validation.
• Long timelines before feedback is gathered from actual users.
• Risks becoming "document-heavy" and stalling innovation.

Agile Model: Iterative and Flexible

Agile is a modern, iterative development model that enables flexibility and rapid prototyping. Work is divided into short cycles called sprints, with each sprint delivering a potentially usable piece of the product. While originally used in software, it’s increasingly adapted for hardware-software co-development in medtech, especially in SaMD (Software as a Medical Device) and IVDs.

1. Product Backlog & User Stories

• Requirements written as User Stories (e.g., “As a lab tech, I want to upload results easily…”).

• Prioritized backlog based on value, risk, and regulatory needs.

• Define sprint goals (2–4 weeks).

• Select backlog items for development and assign tasks.

• Code, hardware sketches, UI/UX prototypes created collaboratively.

• Continuous integration (CI) ensures rapid builds and testing.

• Emphasis on cross-functional involvement (QA/RA, clinical, marketing).

• Each feature is tested before sprint ends (unit, integration, automated tests).

• Some tests may serve dual purposes: engineering + design verification.

• Team presents working increment to stakeholders for review.

• Discuss what went well, what didn’t, and how to improve next sprint.

• Working software (or prototypes) can be deployed for stakeholder feedback or early validation activities.

Choosing the right product development methodology isn’t about picking sides—it’s about aligning your process with both regulatory obligations and product innovation goals. Waterfall offers structure and predictability, Agile offers speed and adaptability, and the Hybrid approach offers the regulatory safety net with the flexibility to innovate.

Objective: This study compares regulatory assessment and approval methods for medical devices and IVDs in the US (FDA), EU (MDR/IVDR), and India (MDR 2017), focusing on global recognition and trust.

Purpose of the Study:

Key Observations and Points for Consideration

1. Global Trust and Recognition of Regulatory Systems

• The US FDA and EU MDR/IVDR systems are considered gold standards globally due to their rigorous, transparent, and science-based assessments.
• FDA 510(k), De Novo, PMA, and the EU’s CE marking process are internationally recognized and often accepted or fast-tracked in other jurisdictions, including the Middle East, Southeast Asia, and Latin America.
• Conversely, India’s CDSCO approvals are not yet globally recognized or considered sufficient as a standalone assurance of safety and performance outside the country.

2. History and Maturity of the Systems

• The US FDA has regulated medical devices since 1976, and the European regulatory framework began evolving formally in the 1990s, reaching new maturity with MDR/IVDR implementation (2021 onwards).
• India began formally regulating devices under the Medical Device Rules (2017), but comprehensive coverage and risk-based classification only became structured recently.
• The comparatively recent implementation of medical device regulations in India results in limited historical performance data and variable enforcement.

3. Scientific Rigor and Data Requirements

• The FDA and EU require clinical evidence, design dossiers, quality system audits (QMS), risk management, usability engineering, and post-market surveillance.
• In India, while many of these elements are now being adopted, the depth of technical review (especially for Class B devices and below) can still be limited to document verification and less on active technical evaluation.
• Clinical performance studies or equivalence pathways in India are not yet harmonized with international standards like ISO 14155, which are routine under FDA/CE evaluations.

4. Role of Notified Bodies and External Expertise

• The EU MDR/IVDR relies on Notified Bodies (NBs) that conduct independent assessments with technical and clinical experts.
• The FDA employs multidisciplinary teams for product-specific evaluations.
• In India, the absence of third-party technical reviewers or NBs often leads to an overburdened centralized regulator, affecting the depth of review and timelines.

5. Transparency, Public Databases, and Stakeholder Trust

• FDA maintains open databases (e.g., MAUDE, 510(k) clearance, PMA approvals, recalls, etc.) which are extensively used by industry and clinicians for benchmarking and safety monitoring.
• The EU has EUDAMED (in stages of public rollout) for similar traceability and vigilance.
• In India, limited access to approval decisions, PMS data, or adverse event reports reduces the ability of stakeholders to verify or trust regulatory outcomes at par with international benchmarks.

This comparative study is not intended to criticize but to highlight opportunities for Indian regulators to further strengthen credibility, consistency, and technical rigor in medical device and IVD regulation.

There is a growing need to build international confidence in India’s approval systems through:

• Transparent technical reviews.
• Stronger post-market surveillance.
• Active engagement with international harmonization programs.
• Potential introduction of third-party evaluators or technical panels.
• Public databases of device approvals and adverse events.

Strengthening these areas will not only reduce over-reliance on US/EU certifications but also establish India as a trusted regulatory hub, especially for Asia-Pacific and developing markets.

EU MDR & IVDR Assessment Techniques – A Product-Centric, Transparent, and Structured Approach

The European Union's Medical Device Regulation (EU MDR - Regulation (EU) 2017/745) and In Vitro Diagnostic Regulation (EU IVDR - Regulation (EU) 2017/746) represent a modernized and strengthened regulatory framework with a product assessment-driven methodology.

Key Features of EU MDR & IVDR Assessment Framework:

1. Single, Streamlined Route for Approval

• Unlike fragmented or document-based systems, EU MDR and IVDR follow a clear, unified route of conformity assessment based on the risk classification of the device.
• Manufacturers must demonstrate compliance with General Safety and Performance Requirements (GSPRs) through Technical Documentation, Clinical Evaluation (MDR) or Performance Evaluation (IVDR), and QMS conformity.
• Assessment is carried out by designated Notified Bodies (NBs) for all but the lowest-risk categories.

2. Focus on Individual Product Assessment

• The system is built around product-specific reviews, with significant emphasis on:
• Design Dossier/Technical File Review
• Device-specific Clinical Data/Performance Evidence
• Post-Market Clinical Follow-up (PMCF) or Post-Market Performance Follow-up (PMPF)
• For Class IIb and III devices (MDR) and Class C and D IVDs (IVDR), assessment is deeply granular, ensuring that each product’s design, labeling, indications, and claims are fully evaluated before CE Marking.

3. Defined Review Cycles and Re-certification Frequency

• EU MDR/IVDR introduces fixed re-certification cycles (5 years) with annual surveillance audits.
• Regular technical file updates, clinical/performance monitoring, and Periodic Safety Update Reports (PSURs) are mandatory.
• This periodic scrutiny helps maintain continuous compliance and ensures ongoing device safety and performance in the market.

4. Integration with Unique Device Identification (UDI)

• Every device must be assigned a UDI—comprising a Device Identifier (DI) and Production Identifier (PI)—to enable precise tracking, recall, and market surveillance.
• UDI allows seamless traceability from the manufacturer to the patient level and is also linked to packaging levels, including reusable and implantable devices.

5. Centralized Transparency via EUDAMED

• The EUDAMED database serves as a publicly accessible, centralized platform providing information on:
• Device registrations and certificates
• Notified Bodies and their scopes
• Clinical investigation data
• Vigilance reports
• Economic operators and authorized representatives
• EUDAMED significantly enhances trust and traceability for all stakeholders: patients, healthcare providers, regulators, and market players.

6. Strengthened Role of Notified Bodies (NBs)

• Notified Bodies are now subject to designation and oversight by EU authorities, and must demonstrate high levels of technical and clinical competence.
• Assessments are device-specific, not just system-based, and NBs are accountable for conducting robust reviews, including:
• Unannounced audits
• Sampling of devices
• On-site inspections and technical interviews

US FDA Medical Device Assessment Techniques – A Control-Based, Product/Item-Centric, and Specific Model

The US Food and Drug Administration (FDA) employs a control-based and product-specific regulatory framework for medical devices and IVDs, focusing on individual device types through assigned Product Codes. This system ensures that each device is assessed with precise and tailored regulatory expectations—beyond just broad risk categories.

Key Features of the US FDA Assessment Framework:

1. Product/Item-Centric Regulation via Product Codes

• Every device type is assigned a unique Product Code that determines:
• Applicable regulatory pathway (510(k), PMA, De Novo, etc.)
• Required performance testing, labeling controls, special controls, and clinical data
• Related device guidance documents, consensus standards, and recognized risk mitigations
• This system enables granular oversight, where even two Class II devices can have entirely different approval requirements based on their intended use and technological characteristics.

2. Control-Based Oversight, Not Just Risk Classification

• The FDA’s model is heavily control-driven, where regulatory requirements are defined per device type—not just by Class I, II, or III.
• Devices are governed by a combination of:
• General Controls (e.g., establishment registration, labeling, QSR compliance)
• Special Controls (device-specific testing, standards, postmarket controls)
• Premarket Approval Controls (scientific evidence, clinical trials)
• Specific manufacturing and quality expectations are enforced per product category, with device-specific validations, process controls, and inspection protocols.

3. Total Product Life Cycle (TPLC) Approach

• FDA emphasizes a Total Product Life Cycle (TPLC) model—managing device safety and effectiveness from concept to post-market.
• TPLC covers:
• Pre-market review (design, testing, labeling, clinical evaluation)
• Market authorization (510(k), PMA, De Novo)
• Post-market monitoring (MDR, recalls, corrections, CAPAs)
• Real-world evidence integration (RWE, device tracking, UDI)
• The TPLC database consolidates information on recalls, adverse events, inspections, and approvals for each Product Code and manufacturer, enhancing regulatory learning and vigilance.

4. Transparency and Public Access to Device-Level Information

• FDA maintains device-specific, open-access databases, including:
• 510(k), PMA, De Novo listings
• MAUDE (adverse event reports)
• TPLC database (safety + compliance history)
• UDI/GUDID database for supply chain traceability
• This enables public and professional confidence, supporting global alignment and benchmarking.

5. UDI-Based Traceability & GUDID System

• FDA mandates Unique Device Identification (UDI) for nearly all marketed devices.
• The UDI is linked to the GUDID database, providing:
• Product attributes
• Packaging levels
• Model/version history
• Issuance of recalls or corrections
• This system enhances traceability across hospitals, supply chains, and patient records.

6. Technical Review by Domain Experts

• FDA reviewers from the Center for Devices and Radiological Health (CDRH) conduct reviews with a science-first mindset, involving:
• Pre-submission meetings (Q-Sub)
• Interactive reviews and deficiency responses
• Clinical and non-clinical specialists
• The agency’s technical depth helps ensure that each product is suitable for its intended use, backed by real-world performance expectations.

🇮🇳 India – A License-Centric, Compliance-Oriented, and Manufacturer-Based Regulatory Model

India’s regulatory system for medical devices, as laid out in the Medical Device Rules (MDR) 2017 under the Drugs and Cosmetics Act, 1940, has made substantial progress in creating a formal structure for medical device oversight. However, the current framework primarily focuses on granting licenses for manufacturing, import, or sale of medical devices, rather than a product-centric, technical approval model.

🔍 Key Characteristics of India’s Medical Device Assessment Model:

1. License-Oriented Regulatory Control

• The MDR 2017 defines the process for issuing licenses to manufacturers and importers.
• The approval is typically for the organization and its facility, not a rigorous technical evaluation of each product.
• The license is granted based on submission of:
• Device Master File (DMF)
• Plant Master File (PMF)
• Quality management certifications (e.g., ISO 13485)
• Basic performance data or equivalent foreign approvals

2. No Product-Specific Technical Review or Public Evaluation

• Unlike FDA (with Product Codes) or EU MDR (with Common Specifications), India does not have defined, category-wise assessment pathways or performance benchmarks for most devices.
• Devices are not subject to systematic product-level clinical evaluation, lab testing, or risk-specific scrutiny as part of the approval process (except under BIS schemes, where applicable).

3. Absence of a Centralized Product Approval System

• India’s MDR framework is not a product approval mechanism in the regulatory sense.
• Product approval, where applicable, is typically done under the Bureau of Indian Standards (BIS)—especially for devices notified under mandatory certification (e.g., thermometers, blood pressure monitors).
• However, BIS certification applies to only a limited list of medical devices, and is focused on conformance to Indian Standards (IS) rather than regulatory lifecycle monitoring.

4. Limited Product Traceability and No UDI Enforcement

• There is no publicly accessible database (like EUDAMED or GUDID) that provides traceability or approval details of each registered medical device.
• Though Unique Device Identification (UDI) has been proposed, it has not yet been mandated or fully integrated into the regulatory system.
• This restricts the ability of users and authorities to track performance, usage, or recall data for specific models or batches.

5. Post-Market Surveillance (PMS) Still in Early Development

• India’s post-market vigilance requirements exist but are limited in scope and poorly enforced.
• There is no Total Product Life Cycle (TPLC) model, and complaint handling/reporting is largely decentralized.
• Manufacturers are not subjected to routine post-market technical reassessments or periodic reviews as seen in EU MDR.

6. Fragmented Oversight: CDSCO for Licensing, BIS for Product Approval

• The CDSCO oversees the regulatory licensing process, while the BIS is responsible for product-level conformance assessment (for a small list of notified devices).
• This dual structure means that India lacks a unified, single-window regulatory system that assesses both organizational capability and technical product performance under one framework.

🔄 Summary Comparison of Indian Model:

Feature	India (MDR 2017)
Regulatory Focus	License to manufacture/import/sell
Product Approval Body	BIS (only for specific notified items)
Product-Specific Assessment	❌ Largely absent (no structured model)
Public Device Database	❌ Not available
UDI System	❌ Not implemented/enforced
Post-Market Vigilance	⚠️ Exists but weakly integrated
Risk-Based Review	✅ Basic classification used, but not deep
Lifecycle Monitoring	❌ No TPLC or defined reassessment intervals

📌 Conclusion:

India’s current medical device regulatory model

India’s current medical device regulatory model is compliance- and license-centric, with an emphasis on manufacturer accountability and basic conformity. However, it lacks:

• A central product approval mechanism
• Risk-specific, product-centric evaluation models
• Public transparency systems like EUDAMED, GUDID, or TPLC

This structural gap makes Indian regulatory approvals less favorable or reference-worthy in international markets or institutional procurement when compared to US FDA or EU MDR/IVDR systems.

Big Update from CDSCO: No Separate Loan License Required for Sterilization of Medical Devices

In a major regulatory update for India's medical device sector, the Drugs Technical Advisory Board (DTAB), during its 92nd meeting held on 24th April 2025, approved a significant relaxation in the licensing process related to device sterilization.

Disclaimer:
This DTAB recommendation is applicable only to the sterilization process when it is outsourced to a third-party facility licensed under Form MD-3 or MD-9. The exemption from loan license does not apply to other outsourced manufacturing activities or to complete contract manufacturing. For all other such scenarios, the requirement of a loan license remains applicable as per the current Medical Device Rules, 2017. Manufacturers are advised to consult their regulatory experts or CDSCO for case-specific guidance.

What’s the Change?

However, as per the new decision:

• Manufacturers holding a valid Form MD-3/MD-4 or Form MD-9/MD-10 license will no longer need to apply for a separate loan license when getting their devices sterilized at a third-party sterilization facility.
• This relaxation applies only if the third-party sterilization facility is already licensed under Form MD-3 or MD-9.

✅ Conditions to Comply

• Documentary evidence of proper sterilization must be submitted to the Licensing Authority at the time of the manufacturing license application.
• The license number of the sterilization site must be clearly mentioned on the product label.

🏭 Who Benefits from This?

• Ease compliance for small and medium-sized device manufacturers.
• Speed up market entry by reducing unnecessary paperwork.
• Enhance operational flexibility without compromising product safety or regulatory oversight.

Background

This update follows the recommendations of the DCC Sub-Committee and reflects CDSCO’s move towards risk-based and practical regulation. It shows a shift towards enabling ease of doing business while ensuring product safety.

This reform brings much-needed relief to medical device manufacturers in India, allowing for efficient and regulated outsourcing of sterilization services. As always, compliance with documentation and labeling requirements remains key.

What’s Next?

While the DTAB’s recommendation marks a significant procedural relief, this change is currently based on expert committee consensus. An official amendment to the Medical Device Rules, 2017 is expected in the coming months or years to formally incorporate this exemption and define the compliance obligations in legal terms. Manufacturers should stay alert for draft notifications and future updates from CDSCO, as these will clarify documentation formats, timelines, and enforcement mechanisms associated with sterilization site disclosures. Until then, strict adherence to the current conditions—especially proper labeling and submission of sterilization evidence—will be essential to maintain regulatory compliance.

GMPvsQMS

The Concepts: Good Manufacturing Practices vs. Quality Management System

GMP (Good Manufacturing Practices) refers to a set of mandatory practices, principles, and procedures laid down by regulatory bodies such as the FDA, WHO, EU-GMP, etc. These practices are standardized, predetermined, and universally applicable across similar product categories to ensure safety, quality, and efficacy.

GMP: Compliance Through Structure

GMP represents a structured and prescriptive approach to ensure that every product batch is safe, effective, and of consistent quality. It focuses on eliminating variability, preventing contamination, and safeguarding public health.

QMS: A System of Quality Ownership

Unlike the fixed, compliance-driven nature of GMP, a Quality Management System (QMS) is designed to be proactive, adaptable, and organization-specific. It is not just about ticking regulatory checkboxes—it's about building a culture of quality ownership across all levels of an organization.

A QMS doesn’t prescribe what to do—it asks you to identify, design, and justify your quality framework based on your organizational context, product risks, customer expectations, and market needs.

Where GMP provides a fixed structure, QMS allows you to build your own architecture—scalable, flexible, and focused on long-term performance. It empowers employees at all levels to take ownership of quality, creating a culture where excellence is not imposed, but internalized.

In essence, QMS is not just about doing things right—it’s about doing the right things, the right way, for your business and your customers.

Predetermined vs. Discovered Requirements: The Core Conceptual Divide

At the heart of understanding GMP and QMS lies a pivotal distinction: GMP operates on predetermined requirements, while QMS is built on discovered, contextual requirements. This single contrast sets the tone for how these systems are implemented, managed, and evolved in practice.

But what does that really mean in practice? More importantly, when are you expected to apply it, and how should it be documented?

• What the Risk-Based Approach is
• When it should be applied across key QMS functions
• How it should be reflected and documented in your quality system

What Is the Risk-Based Approach?

A risk-based approach means that an organization must have a clear understanding of the risks it is exposed to, and must apply proportionate measures to effectively mitigate or control those risks.

It is not optional—it is a foundational principle that supports compliance with all other QMS requirements. Risk-based thinking is embedded throughout ISO 13485, as well as other related standards and regulations.

• Identifying and assessing risks that could impact product quality, patient safety, or compliance

• Applying mitigation controls at the appropriate levels, such as:

  Top-level documents (e.g., Quality Manual, Risk Management Plan)
• Design and development documents (e.g., risk analysis, usability reports)
• Standard Operating Procedures and Work Instructions
• Visual aids like warning labels, signs, or precautions
• Tailoring the level of control based on the significance of the risk

WHEN Is the Risk-Based Approach Applied in QMS?

In ISO 13485 and related standards, the risk-based approach is not confined to product safety (as addressed in ISO 14971), but extends across all quality system processes. The application of risk should guide how activities are planned, executed, controlled, and documented—with greater emphasis placed on higher-risk areas.

HOW Is Risk-Based Approach Documented in the QMS?

This is where global regulatory writing plays a key role. It is more than just putting data into a file it means creating clear, accurate, and well-structured documents that meet the needs of different regulators, each with its own rules and expectations.

For example, the European MDR requires detailed Clinical Evaluation Reports (CERs), the US FDA expects structured submissions like 510(k) or PMA, and China’s NMPA and Japan’s PMDA have their own unique dossier formats. The way a device’s safety and performance are described depends on how well these documents are written.

International efforts, like the IMDRF’s Summary Technical Documentation (STED) and the MDSAP audit program, have helped reduce repeated work. Still, companies face challenges such as keeping terminology consistent, providing enough clinical evidence, and showing clear risk-benefit analysis across regions.

This article will explain the basics of global regulatory writing in medical devices, the main challenges companies face, and the best practices to create documentation that speeds up approvals and ensures strong compliance worldwide.

Global Frameworks Influencing Regulatory Writing

IMDRF (International Medical Device Regulators Forum)

The IMDRF is a group of leading regulators — including the US FDA, EU authorities, Japan’s PMDA, and others — that aims to bring greater consistency in medical device regulations worldwide.

One of its most important contributions is the Summary Technical Documentation (STED) format. STED provides a standardized outline for technical documentation, covering key areas such as device description, design and manufacturing information, risk management, clinical evidence, and labeling.

For manufacturers, this means they can prepare a core technical file in the STED format and then adapt it for local markets. While not all regulators accept STED directly, it helps companies structure their documents in a way that is clear, consistent, and globally relevant.

MDSAP (Medical Device Single Audit Program)

The MDSAP is another major step toward harmonization. Instead of being audited separately by each regulator, manufacturers can undergo one audit that is recognized by several authorities — including the US FDA, Health Canada, Brazil’s ANVISA, Japan’s PMDA, and Australia’s TGA.

This audit is based on ISO 13485:2016 (the international quality management system standard for medical devices), combined with country-specific requirements.

For regulatory writing, MDSAP brings several advantages:

• It encourages companies to maintain consistent quality documentation.
• It reduces the need to duplicate information for different audits.
• It supports a more streamlined approach to preparing regulatory submissions across multiple markets.

The Process of Regulatory Writing in Medical Devices

Regulatory writing is more than compiling documents — it is about turning complex technical data into a structured story of safety, quality, and performance that satisfies global regulators. The process generally follows a systematic flow:

1. Planning and Scoping

Before any writing begins, the scope of the submission must be defined. This involves identifying the type of regulatory pathway (EU MDR Technical File, FDA 510(k), PMA, or a global submission) and mapping out all required documents. A cross-functional team — including Regulatory Affairs, R&D, Clinical, Manufacturing, and Quality — comes together to align expectations.
Under EU MDR, this step ensures that documents such as the Clinical Evaluation Report (CER), Risk Management File, PMS Plan, and Instructions for Use (IFU) are listed upfront.

2. Data Collection and Evidence Gathering

Strong writing depends on strong data. At this stage, inputs are collected from across the organization, including:

• Design and development records
• Risk management documents (ISO 14971)
• Clinical data (clinical investigations, literature reviews, registries)
• Bench testing, biocompatibility, sterilization, and electrical safety reports
• Post-market surveillance (complaints, vigilance reports)

Without this foundation, there is a huge risk of documents being incomplete or inconsistent.

3. Drafting the Documentation

This is where regulatory writers transform raw data into structured, regulator-ready documents. Each file must follow the correct format such as the IMDRF STED template, MDR Annex II, or FDA 510(k) checklist. The writing must be clear, scientific, and evidence-based, avoiding marketing language.
For example When drafting a CER, every clinical claim must be directly supported by published data, clinical trial results, or real-world evidence.

4. Internal Review and Cross-Functional Feedback

Drafts are reviewed by subject matter experts across functions. The goal is to check for scientific accuracy, consistency, and traceability between documents. Regulatory writers play a key role in making sure that risks, benefits, and claims are aligned across CER, PMS, Risk Management, and Labeling.
Imagine If a risk is identified in the CER but not reflected in the IFU warnings, reviewers will flag it for correction.

5. Quality Control (QC)

Before submission, every document undergoes a detailed quality check. This includes editing for clarity and consistency, verifying references, and running compliance checks against regulatory requirements. QC acts as the last line of defense against rejection due to missing or inconsistent information.

6. Finalization and Submission

Once approved internally, documents are compiled into the submission package. Depending on the market, this could be an electronic submission (like FDA’s eSTAR) or a structured technical file for review by a Notified Body or national authority.
Example: For FDA, the package is submitted via the eSTAR template; for EU MDR, the technical documentation is sent to a designated Notified Body.

7. Post-Submission Maintenance

Regulatory writing does not end at submission. Authorities may request clarifications or additional evidence. In addition, documents must be maintained throughout the device lifecycle with updates for new data, post-market reports, and periodic safety reviews.
For example Under MDR, manufacturers must submit a Periodic Safety Update Report (PSUR) annually for higher-risk devices.

Best Practices for Global Submissions

Writing regulatory documents for multiple markets is challenging, but following certain best practices can make the process smoother, more consistent, and more efficient.

1. Build Documentation Using IMDRF STED Format as the Backbone

The IMDRF’s Summary Technical Documentation (STED) provides a global structure for technical files. By drafting documents in this format, manufacturers create a universal core file that contains all key elements: device description, risk management, clinical evidence, and labeling.

Practical Steps:

• Start with a “core dossier” in STED format and then layer in market-specific requirements.
• Use STED headings as a checklist during planning to ensure no critical document is missed.
• Create a “gap matrix” mapping STED content against EU MDR Annex II/III, FDA 510(k)/PMA checklists, and other local requirements.

Example: A company preparing for both EU MDR and FDA 510(k) submissions can start with the STED structure, then adapt specific sections — such as the CER for MDR or the substantial equivalence section for FDA — without rewriting the entire file.

Pitfall to Avoid: Writing first for one market (say FDA) and then retrofitting for MDR. This often leads to mismatched terminology and duplicated effort.

2. Ensure Traceability Across Documents

Consistency is one of the most important principles in regulatory writing. Every claim in one document should connect logically to other documents. This is called traceability.

Risk Management (ISO 14971) must align with Clinical Evaluation Reports (CER), Post-Market Surveillance (PMS) plans, and the Instructions for Use (IFU).

Practical Steps:

• Maintain a “Traceability Matrix” that links risks → mitigations → clinical evidence → labeling.
• During internal reviews, ask: “If I pick one risk or claim, can I find it consistently across all files?”
• Use cross-references where possible instead of duplicating content (e.g., CER directly cites the Risk Management File).

Example: If the IFU warns users about a risk of device overheating, that risk should also appear in the risk analysis, be discussed in the CER as part of the risk-benefit assessment, and be tracked in PMS reports.

Pitfall to Avoid: Making last-minute changes in the IFU or marketing material without updating the technical documentation — a common cause of Notified Body findings.

3. Use Modular Writing for Reusability

Global submissions often ask for the same type of information but in different formats. Instead of rewriting content every time, companies can use modular writing — breaking documents into smaller sections (modules) that can be reused.

Practical Steps:

• Think of each section as a “building block” — e.g., device description, materials used, sterilization method, biocompatibility, etc.
• Store these blocks in a central library or document management system (DMS) so teams don’t waste time searching or rewriting.
• Always keep modules updated with version numbers or dates so everyone knows which is the latest approved version.

Example: The device description, manufacturing process, and biocompatibility data are the same for both EU MDR and US FDA submissions. By keeping these as reusable modules, teams can simply adapt them to the format needed — saving effort and ensuring consistency across regions.

Pitfall to Avoid: Don’t just copy-paste from old submissions. This often brings in outdated information or conflicting data. Modular libraries prevent this by ensuring only the latest version is used everywhere.

4. Leverage Document Management Systems (DMS)

With multiple submissions and frequent updates, managing documents manually is error-prone. Modern Document Management Systems (DMS) like Veeva, Master Control, or SharePoint-based QMS systems help maintain version control, automate workflows, and support audit readiness.

Practical Steps:

• Use DMS to lock approved versions — preventing teams from accidentally working on outdated files.
• Set automated review workflows so SMEs (subject matter experts) can approve content in sequence.
• Build a metadata system (e.g., tagging documents by device family, geography, or submission type) to quickly find and update the right content.
• Train all contributors (R&D, Clinical, QA, RA) on how to use the DMS to avoid email chaos.

Example: If a clinical evidence section is updated in the CER, a DMS ensures that the same update is automatically tracked for the Technical File and linked documents, avoiding inconsistencies.

Pitfall to Avoid: Treating DMS as just a “file storage system.” Without structured workflows and metadata, it becomes a fancy shared drive.

Note:

Companies that succeed with global submissions treat regulatory writing as a content management process, not just a document-writing exercise. By using STED as the backbone, enforcing traceability, modularizing content, and leveraging technology, they reduce duplication, avoid costly rejections, and accelerate market access.

The Future of Global Regulatory Writing

The world of regulatory writing for medical devices is evolving rapidly. It’s no longer just about preparing static PDFs; regulators are moving toward digital-first, evidence-driven, and AI-assisted submissions. Here’s what the future looks like:

1. Digital Submissions: FDA eSTAR and EU EUDAMED

Regulators are shifting from paper/PDF-based dossiers to structured digital templates.

• FDA eSTAR: An interactive submission template for 510(k) and De Novo. It guides applicants section-by-section, flags missing data, and ensures consistency with FDA expectations.
• EU EUDAMED: A centralized EU database where manufacturers upload device, company, and vigilance data directly.

Example: Instead of submitting a 200-page PDF, future FDA submissions will be uploaded as structured forms where each data field is validated automatically. Missing test reports will be flagged instantly.

2. Increasing Reliance on Real-World Evidence (RWE)

Clinical evidence is expanding beyond traditional clinical trials. Regulators are accepting post-market data, registries, and even wearable/device usage data as part of safety and performance evaluations.

Example: A Class II cardiac monitoring device in the U.S. may submit PMS registry data showing low adverse event rates, which can then be reused in an MDR CER update to strengthen the risk-benefit case.

3. Artificial Intelligence (AI) in Regulatory Writing

AI is emerging as a co-pilot for regulatory writers. It won’t replace human judgment, but it will automate time-consuming tasks:

• Literature reviews: AI can scan thousands of studies, extract key outcomes, and suggest relevance.
• Formatting & consistency checks: Ensures terminology, numbering, and references match across documents.
• Quality control (QC): Detects gaps in traceability (e.g., a risk mentioned in RM but missing in CER).

Challenges in Global Regulatory Writing

Writing for global markets sounds efficient, but in practice it comes with major hurdles:

1. Different regional expectations – A CER for EU MDR is narrative-driven, while FDA 510(k) is checklist-oriented, and NMPA may demand additional testing. One device, but three very different stories.
2. Maintaining consistency – A risk highlighted in the risk file must also appear in the IFU, CER, and PMS plan. Even small gaps can trigger questions or delays.
3. Managing large volumes of data – Post-market surveillance, clinical studies, and real-world evidence generate a flood of information. Writers must extract what’s relevant without overwhelming regulators.
4. Frequent regulatory changes – MDR guidance updates, FDA’s move to eSTAR, or Japan’s PMDA clarifications force teams to constantly adjust.
5. Cross-functional dependencies – Regulatory writers rely on timely input from R&D, Quality, Clinical, and Marketing. Misalignment across these groups can slow submissions.
6. Time and resource pressure – Market launch deadlines often demand speed, but poor-quality writing risks rejections or lengthy review cycles.

Global regulatory writing is not just paperwork — it is the bridge between innovation and market access. Strong writing ensures regulators understand the device’s safety, performance, and clinical value without confusion.

Best practices such as using IMDRF STED as a universal structure, ensuring document traceability, applying modular writing, and adopting digital document systems help companies reduce duplication and maintain consistency across regions.

Organizations—especially global manufacturers—are expected to comply with a wide range of standards and regulations. These may include ISO 9001 (Quality Management), ISO 14001 (Environmental Management), ISO 45001 (Occupational Health & Safety), ISO 13485 (Medical Devices), IATF 16949 (Automotive Quality), along with diverse regional and customer-specific requirements.

While each standard serves a specific purpose, the challenge arises when organizations manage them as independent systems. This often leads to overlapping requirements, duplicated documentation, increased audit frequency, and unnecessary administrative burden. Instead of enabling efficiency, the coexistence of multiple stand-alone systems can create silos, confusion among employees, and higher operational costs.

For manufacturers operating across multiple disciplines and geographies, the complexity only multiplies. Maintaining separate management systems at each site or for each standard results in:

• Increased documentation and compliance workload.
• Higher costs due to duplication of resources.
• Difficulty in aligning processes across global operations.

In today’s competitive economy, where efficiency, agility, and cost-effectiveness determine business success, organizations can no longer afford fragmented approaches. This is where an Integrated Management System (IMS) emerges as a strategic solution. By consolidating multiple standards into a single, streamlined framework, IMS helps reduce redundancy, improve system performance, and ensure global consistency—enabling organizations to shift their focus from over-compliance to operational excellence.

The Need for IMS in Multi-Disciplinary & Global Operations

As organizations expand across industries and geographies, the complexity of managing multiple management systems intensifies. Each site or business unit may be subject to different regulatory requirements, customer expectations, and certification standards. Without a unified framework, this often results in duplicated efforts, misaligned priorities, and rising operational costs.

An Integrated Management System (IMS) provides a consolidated approach that addresses these challenges by:

For manufacturers competing in a highly regulated, cost-sensitive, and customer-driven environment, IMS is not just a tool for compliance—it is a strategic enabler of efficiency, resilience, and global competitiveness.

India’s medical device sector has emerged as one of the fastest-growing segments within the healthcare ecosystem. Over the past decade, the industry has witnessed a surge in demand driven by rising healthcare awareness, expanding hospital infrastructure, and technological innovation. In 2023, the Indian medical device market was valued at approximately US$ 11 billion, underscoring its increasing significance in both domestic and global healthcare supply chains.

Looking ahead, projections estimate that the sector will expand to nearly US$ 50 billion by 2030, reflecting a compound annual growth rate (CAGR) of 16.4%. On the surface, such numbers suggest robust growth and a promising future for the industry. However, this raises a critical question: does this impressive CAGR truly reflect innovation, wider accessibility, and adoption of medical devices across India—or is it being significantly driven by rising device prices and inflationary pressures?

Understanding CAGR in the Medical Device Context

The Compound Annual Growth Rate (CAGR) is a commonly used metric to describe how fast a market is growing over a given period. In simple terms, CAGR represents the smoothed average annual growth rate of an investment, industry, or market between two specific years. Unlike year-on-year growth, which may fluctuate due to seasonal demand or sudden shocks (such as COVID-19), CAGR provides a steady trend line that shows how the market would have grown if it expanded at the same rate every year.

For example, if India’s medical device market was valued at US$ 11 billion in 2023 and is projected to reach US$ 50 billion by 2030, the implied CAGR is 16.4%. This figure suggests a strong and sustained pace of growth. But behind this smooth number lies a complex reality.

CAGR in the Medical Device Sector: What It Captures

CAGR in medical devices is typically calculated on the basis of:

Thus, CAGR in this sector reflects not just the volume of devices sold, but also the pricing trends, import dependency, regulatory changes, and exchange rate impacts that influence overall revenues.

How Price Inflation Can Inflate CAGR

A key limitation of CAGR is that it does not differentiate between real growth (more people gaining access to affordable devices) and nominal growth (higher revenue simply because prices are rising). For instance:

• If the cost of a stent doubles due to higher certification and import costs, the market value increases, even if the same number of stents is sold.
• Rising input costs, distributor margins, and compliance expenses all push up prices, contributing to a larger “market size” without necessarily expanding device adoption.

This means that while investors and policymakers may see a 16.4% CAGR as evidence of a booming sector, the reality on the ground for patients and hospitals could be very different. Higher device prices might be inflating the industry’s growth figures, while simultaneously reducing affordability and accessibility.

Why This Matters

Understanding the true drivers of CAGR is vital for:

• Policy-makers, who need to ensure growth is inclusive and not just price-driven.
• Investors, who may misinterpret inflation-led expansion as sustainable demand growth.
• Healthcare providers and patients, who ultimately experience the burden of price inflation in the form of higher treatment costs.

In short, CAGR in the medical device industry can be both a measure of opportunity and a potential illusion of progress if not examined against the backdrop of inflationary forces.

Although wording varies slightly, the core requirement is universal: the manufacturer must clearly define what the device is meant to do, for whom, and under what conditions.

A precisely written Intended Use is not just a technical detail—it is the central element that determines the entire regulatory strategy of a medical device. It directly influences:

Because of this, every aspect of a device’s safety, performance, and compliance ultimately traces back to a clear and consistent Intended Use statement. A poorly worded or overly broad intended use can lead to regulatory rejection, additional testing, misclassification, or even safety risks. In contrast, a well-defined intended use aligns the device’s design, evidence, labeling, and market positioning into one cohesive and compliant framework.